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EXECUTIVE SUMMARY
Whether caring for an individual patient with an infec-
tious disease or responding to a worldwide pandemic,
the rapid and accurate establishment of a microbial
cause is fundamental to quality care. Despite dramatic
advances in diagnostic technologies, many patients
with suspected infections receive empiric antimicrobial
therapy rather than appropriate therapy dictated by the
rapid identification of the infectious agent. The result is
overuse of our small inventoryof effective antimicrobials,
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whose numbers continue to dwindle due to increasing levels of
antimicrobial resistance.
New tests are needed that can identify a specific pathogen or
at a minimum, distinguish between bacterial and viral infections,
and also provide information on susceptibility to antimicrobial
agents. Tests should be easy to use and provide a rapid result
(ideally within an hour) to have a positive impact on care.
Results must be effectively communicated to the healthcare pro-
vider or public health practitioner and may require the interpre-
tive expertise of an infectious diseases physician or clinical
microbiologist. The infectious diseases physician can serve as a
bridge between the laboratory and the healthcare provider to
ensure the proper use and interpretation of diagnostic testing.
The expertise of the infectious diseases clinician becomes more
important with the advent of newer, more complex tests. The
availability of needed tests will lead to improvements in clinical
outcomes for patients, antimicrobial stewardship, detection and
tracking of disease outbreaks, and investigation of unknown
pathogens, both in the United States and globally.
Emerging technologies enable the detection and quantification
of pathogen burden with new speed, sensitivity, and simplicity of
use. However, there are significant challenges to the develop-
ment, regulatory approval, and clinical integration of diagnostic
tests that use these new technologies. The need for diagnostics
that advance clinical care and public health has never been
greater, and there is a critical window of opportunity to harness
new technologies to address the greatest unmet needs.
In this Infectious Diseases Society of America (IDSA) policy
paper, we review the current diagnostic landscape, including
unmet needs and emerging technologies, and assess the chal-
lenges to the development and clinical integration of improved
tests. To fulfill the promise of emerging diagnostics, IDSA pre-
sents recommendations that address a host of identified barri-
ers. Achieving these goals will require the engagement and
coordination of a number of stakeholders, including Congress,
funding and regulatory bodies, public health agencies, the diag-
nostics industry, healthcare systems, professional societies, and
individual clinicians.
RECOMMENDATIONS
Stimulate Diagnostics Research and Development
1. Because of the need for research and development (R&D) to
translate new technologies into practical tests, federal funding
agencies should prioritize diagnostics R&D through innovative
funding mechanisms and clinical research infrastructure.
(a) The National Institutes of Health (NIH) should in-
crease funding of diagnostics research, especially through
the Small Business Innovation Research (SBIR) program
and the U01 funding mechanism.
(b) NIH should ensure that the peer review process for
diagnostics grant submissions includes study sections with
appropriate expertise to evaluate feasibility and clinical
applicability, as well as scientific merit.
(c) Biorepositories or other infrastructure to facilitate
the procurement of critical clinical specimens should be
developed and maintained to aid in the validation and
verification of novel diagnostic methods (see Appendix B
for a model of how a repository could work).
2. Because of the impact on patient care, public health sur-
veillance, and biodefense, Congress should support increased
appropriations for diagnostics activities, including to:
(a) NIH, including the SBIR diagnostics program at the
National Institute of Allergy and Infectious Diseases
(NIAID) and the Point-of-Care Technologies Research
Network at the National Institute of Biomedical Imaging
and Bioengineering;
(b) The Biomedical Advanced Research and Develop-
ment Authority for the advanced development of innova-
tive infectious diseases diagnostics; and
(c) The Centers for Disease Control and Prevention
(CDC) for the Advanced Molecular Detection (AMD) ini-
tiative, designed to acquire updated technologies for public
health surveillance.
3. Because of the need to accelerate specific areas of diagnos-
tics development, such as rapid diagnostics and diagnostics for
resource-limited settings, Congress should enact:
(a) Legislation in support of a tax credit to cover 50%
of clinical research costs for qualifying rapid diagnostics;
and
(b) The 21st Century Global Health Technology Act (H.
R. 1515), which will strengthen health R&D programs at
the United States Agency for International Development
(USAID) and require no new funding.
4. To address the highest priority unmet needs, federal in-
centives to stimulate diagnostics R&D should focus on tests
with the following characteristics:
(a) Performed directly from accessible, minimally inva-
sive clinical specimens, such as blood, respiratory sam-
ples, urine, and stool;
(b) Able to rule out infection with high certainty (eg,
≥98% negative predictive value) as a first step for a variety
of clinical syndromes;
(c) Incorporating biomarkers that are either pathogen-
or host-derived and capable of indicating host response to
a pathogen or further classifying clinically significant in-
fectious processes into relevant categories (eg, bacterial,
fungal, viral, or parasitic);
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(d) Panels targeting themost important clinical syndromes,
including central nervous system (CNS) infections, sepsis
and bloodstream infections, respiratory tract infections, and
most important pathogens, including fungal agents;
(e) Special considerations for pediatric use, especially
for tests with biomarkers and syndromic panels;
(f ) Pathogen-specific diagnostics, linked to drug resis-
tance information;
(g) Rapid diagnostics that substantially improve upon
the “time to result”metric of currently approved tests;
(h) Point-of-care diagnostic testing that allows for usage
in many clinical settings, including physician offices; and
(i) Improve outbreak detection andmaintain public health
surveillance capability.
Expedite Integration of Improved Diagnostic Tests Into Patient
Care
1. To ensure that diagnostic tests can be conducted, and
results communicated and acted upon rapidly around the
clock, appropriate infrastructure is needed at healthcare institu-
tions, including personnel and information technology.
(a) The Centers for Medicare and Medicaid Services
(CMS), in coordination with the Office of the National Co-
ordinator for Health Information Technology, should en-
courage healthcare systems to improve electronic medical
record systems, including the establishment of electronic re-
porting of laboratory results to health departments.
(b) CMS should provide incentives for healthcare facilities
to form dedicated multidisciplinary teams (including infec-
tious diseases consultants, other physicians, nurses, phar-
macists, clinical microbiologists, infection preventionists,
and the antimicrobial stewardship team) to develop proto-
cols for responding to clinically significant test results.
(c) Congress and the Administration should fund informa-
tion technology solutions for data integration and dissemina-
tion, to be developed locally within healthcare institutions.
(d) Diagnostic companies should work with healthcare
systems to ensure that new diagnostics are integrated into
current laboratory workflow practices.
2. Healthcare systems should use clinical guidelines from
IDSA and other professional societies to guide patient manage-
ment decisions regarding the use of diagnostics.
3. Outcomes research should be supported that addresses
the need for data on diagnostics use in varied clinical settings
and data to document the effect of diagnostic testing on the in-
dividual patient and the healthcare system.
(a) Funding bodies (including the NIH, the Agency for
Healthcare Research and Quality [AHRQ], and the Patient-
Centered Outcomes Research Institute) and industry
should fund outcomes research to determine whether use
of specific tests improves patient outcomes (eg, morbidity
and mortality) and/or resource utilization.
(b) Healthcare systems should be encouraged to develop
cost-effectiveness models that assess the impact of diag-
nostics on all facets of patient care, eg, mortality, length of
stay, use of antimicrobials, and infection control practices.
Address Regulatory Challenges to Diagnostics R&D
1. There is an urgent need for Congress and the NIH to
clarify and revise conflict of interest policies to allow collabora-
tion between diagnostic companies, diagnostic laboratories,
and key opinion leaders. It takes the coordinated expertise of
sponsors, academicians, and laboratory personnel to conduct
high-quality clinical trials that meet US Food and Drug Admin-
istration (FDA) regulatory requirements.
2. Because it would severely limit the conduct of diagnostics
research, the Department of Health and Human Services
should withdraw the draft proposal to institute a new informed
consent requirement for research with de-identified residual
clinical samples, outlined in the 2011 Advanced Notice of Pro-
posed Rulemaking for human subjects research protections (ie,
the Common Rule).
3. Congress should provide incentives and support for insti-
tutions to save de-identified specimens when possible for the
purposes of new test development, FDA clinical evaluations,
and assay verification and validation.
4. In the interest of addressing unmet patient need, the FDA
Center for Devices and Radiological Health (CDRH) should
revise the guidance for research use only/investigational use
only (RUO/IUO) devices and permit use in cases where there
are no other diagnostic options.
5. FDA CDRH should exercise its flexibility and exempt
companies from redemonstrating the clinical validity of a novel
diagnostic product after multiple studies for similar products
have been conducted.
6. FDA CDRH and the FDA Center for Drug Evaluation
and Research should provide greater clarity in guidance for the
codevelopment of drugs and diagnostics.
7. FDA should assist in the development of strategies to pre-
serve specimens for public health surveillance purposes, for
example, by asking developers of new technologies to include a
“public health plan” with their submission.
Ensure Appropriate Levels of Reimbursement for Diagnostic
Testing
1. CMS should eliminate the wide regional variations in re-
imbursement for diagnostic testing and ensure that reimburse-
ment covers the cost of testing at a minimum.
2. To improve the adoption of new tests, CMS should sim-
plify, expedite, and increase the transparency of the process for
assigning new Current Procedural Terminology (CPT) codes
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and subsequent incorporation of new codes for laboratory tests
into the Clinical Laboratory Fee Schedule.
3. To improve the process of Medicare payment rate deter-
mination for diagnostic testing, Congress should enact the Di-
agnostic Innovation Testing and Knowledge Advancement Act
of 2013 (H.R. 2085 in the 113th Congress).
Encourage Adoption of New Tests
1. To provide laboratories with greater clarity about the pro-
cesses for clinical validation or verification for new diagnostic
assays, CMS should work to harmonize recommendations
under the Clinical Laboratory Improvement Amendments (CLIA)
with those from various professional societies and organiza-
tions (eg, Clinical and Laboratory Standards Institute [CLSI],
College of American Pathologists).
2. There is an urgent need for all stakeholders to work to-
gether to develop guidelines on how to establish reference
methods for new technologies that are more sensitive and spe-
cific than the existing “gold standard.”
3. CMS should discourage facilities that do not receive
enough specimens to maintain competency and accuracy from
conducting highly complex diagnostic testing.
4. Diagnostic companies should convert highly complex
assays to moderately complex tests that can be performed in a
variety of clinical settings using “walk-away technology.”
5. To ensure an adequate pool of well-qualified profession-
als, Congress and the Health Resources and Services Adminis-
tration (HRSA) should work with professional societies to
support the recruitment and retention of clinical microbiolo-
gists and medical technologists.
6. Diagnostic companies should promote training in new
technologies for the laboratory workforce.
Educate Healthcare Providers on the Use of Diagnostics
1. AHRQ and HRSA should fund and encourage healthcare
institutions and professional societies to strengthen educational
programs that disseminate the results of diagnostics-focused
health sciences research and that inform physicians about the
utility of available tests.
2. Professional societies, educational institutions, and other
entities involved in the education of clinicians, including gradu-
ate medical education, continuing medical education, and
maintenance of certification, should ensure that education in-
cludes the performance of diagnostic tests, interpretation of test
results in individual clinical settings with varied patient popula-
tions, available guidelines, and cost of testing.
3. Professional societies and other organizations should
include clinical microbiology experts in the development of
clinical practice guidelines that make recommendations on the
use of diagnostic tests.
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INTRODUCTION
Diagnostic tests play a major role in the clinical care of patients
with infectious diseases, including detection of specific patho-
gens, discovery of new pathogens, determining appropriate
therapy, monitoring response to therapy, assessing prognosis,
and disease surveillance. Despite the increased use of rapid
tests and the availability of molecular and proteomics-based
tests, diagnostics are not being integrated into clinical care opti-
mally. Integration is influenced by the clinical syndrome, the
availability of and access to appropriate diagnostics, the place of
service, and the experience and knowledge of the healthcare
provider. The goal of this paper is to increase awareness of the
current and potential value of infectious diseases diagnostics
for patient care and public health, and to promote further de-
velopment of needed diagnostics.
Antonie van Leeuwenhoek (1632–1723), the “father of the mi-
croscope,” changed the course of infectious diseases when he
enabled the visualization of the microbial world, a world no one
had imagined. Since then, the goal of infectious diseases diagnos-
tics has been to detect the source of the infection and enable an
appropriate response. Although we have better stains, better mi-
croscopes, and novel agar media types, standard microscopy and
culture methods have not changed dramatically in more than a
century. Recently, new technologies have brought great advances
in infectious diseases diagnostics. The field of clinical microbiol-
ogy is currently in transition and standard-of-care testing is now
a hybrid of old and new methodologies.
The evolution of infectious diseases diagnostics has resulted
from advances in chemistry, immunology, molecular biology, en-
gineering, automation, and nucleic acid amplification. It is now
possible to determine the specific etiology of a patient’s infectious
disease in the hospital, clinic, office, remote village, or even a pa-
tient’s home. With automation and highly multiplexed assays, in-
dividual pathogens can be readily identified in a wide variety of
specimen types including blood, urine, tissue, mucosal swabs, ce-
rebrospinal fluid (CSF), respiratory secretions, and stool samples.
Evolution of Diagnostic Assays Through Present Day
The Gram stain was, and still is, often the first line of diagnosis
for the infectious diseases consultant. Microscopy, with or
without staining, permits the diagnosis of many infectious dis-
eases, for example, acute gonococcal urethritis, primary syphi-
lis, differentiation of gram-positive or gram-negative pathogens
on sputum smears, and detection of Mycobacterium tuberculo-
sis and similar pathogens. Monoclonal antibodies, tagged with
fluorescein, enable microbiologists to visualize organisms such
as Legionella pneumophila that do not stain well with conven-
tional stains, or to enhance detection of pathogens such as
M. tuberculosis or Pneumocystis jirovecii.
Evolving bacterial culture methods and eventually viral
tissue culture further amplified the ability to detect specific
pathogens, enabled recovery of the pathogens in pure culture,
and allowed for susceptibility testing of bacteria against specific
antimicrobial agents. However, a major disadvantage of
culture-based methods is the time needed for culture growth.
Table 1 provides a snapshot of the time required for pathogen
identification using various diagnostic methods.
Developments in biochemistry enabled the detection of a spe-
cific metabolic product; for example, the time required for detec-
tion and identification of the slow-growing M. tuberculosis is
substantially reduced by the radiometric detection of C14-labeled
carbon dioxide produced by the metabolism of palmitic acid.
Antibody detection by enzyme immunoassay (EIA) and
enzyme-linked immunosorbent assays is enhanced by the use of
analytic detectors, such as the spectrophotometer, fluorometer,
luminometer, and radioactive counter. The specificity of antigen
and antibody detection is increased by the use of monoclonal an-
tibodies and recombinant antigens. Modern antibody panels can
detect multiple antigens and/or antibodies or the presence of
IgM or IgA antibodies within hours of specimen submission. Ex-
amples of antigen detection with specific antibody include rapid
testing for Streptococcus pyogenes in the throat; cryptococcal
antigen in blood and CSF; and detection of the antigens of Strep-
tococcus pneumoniae, Legionella pneumophila serogroup 1, and
Histoplasma capsulatum in urine. These assays are more rapid
than culture-based tests and do not require cultivation of viable
organisms. However, they do not increase sensitivity over that of
culture, nor do they provide information on susceptibility of mi-
croorganisms to antimicrobial drugs.
The last2decadeshavewitnessed thedevelopmentofpolymerase
chain reaction (PCR) and other nucleic acid–based amplification
Table 1. Historical Evolution of Diagnostic Methods and the
Associated Time Required for Pathogen Identification
Diagnostic Method
Time for Pathogen
Identification
Microscopy Morphology in minutes
Gram stain General category in minutes
Culture and phenotypic biochemistry
on/in artificial media (bacterial,
mycobacterial, fungal)
Days to weeks
In vitro antimicrobial susceptibility Days to weeks
Acute and convalescent antibody Weeks
Monoclonal antibodies Hours
Antigen detection Minutes to hours
Real-time polymerase chain reaction
for microorganisms and drug
resistance genes
One to several hours
Mass spectrometry Seconds to minutes, after
growth on/in media
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technologies (NAATs) that detect microbial and host genetic se-
quences with great sensitivity and specificity. Nucleic acid amplifi-
cation methods are increasingly employed to detect and often
quantitate an ever-increasing number of pathogens, for example,
human immunodeficiency virus (HIV), hepatitis B virus (HBV),
hepatitis C virus (HCV), cytomegalovirus (CMV), and BK virus.
The use of molecular diagnostics for quantifying HIV type 1
(HIV-1), HBV, and HCV revolutionized the development of anti-
retroviral drugs, which could be utilized in the management and
treatment of viral infection. We are at the beginning of a signifi-
cant transformation in diagnostics and it is critical to capitalize
on the current opportunity to invest in the most needed diagnos-
tics and enable the utilization of improved diagnostics for both
clinical management and public health surveillance.
SECTION I: VALUE OF INFECTIOUS DISEASES
DIAGNOSTICS
Although an economic value of infectious diseases diagnostics is
not always easily quantifiable, it is clear that diagnostics play a
valuable and critical role in the care of patients with and those at
risk of developing an infectious disease. Diagnostics clarify the
etiology of the patient’s illness, influence treatment modalities,
and enable public health surveillance. Diagnostics are applied to
different patient populations in settings ranging from outpatient
clinics and hospital intensive care units (ICUs) to point-of-care
(POC) tests on the battlefield. Advances in POC testing have
demonstrated that it is possible for sample collection and testing
to be done in remote settings, away from the standard hospital
and laboratory healthcare settings. If the tests are simple enough,
collection and testing can be conducted by minimally trained
personnel without extensive technical skills, or even at home by
the patient. POC testing may also be of value in the determina-
tion of whether a higher level of care (eg, outpatient to inpatient)
is indicated. Interpretation of test results, however, requires
putting the data into the appropriate clinical context by a health-
care provider. Increasingly, this is best done by an infectious dis-
eases consultant, who may or may not be on site.
The characteristics of an ideal diagnostic test include accura-
cy wherever used; heat-stable reagents with an extended shelf
life; portability; minimal technical skills for operation; rapid,
sensitive, and specific results; on-demand testing capability or
minimal batch sizes; low-cost and/or cost-effective for patient
care; and suitable for a broad range of clinical samples. Current
antigen and nucleic acid detection tests meet some, but not all,
of these idealized criteria.
Diagnosis and Patient Management
A primary role for diagnostics is to identify disease and enable
management of the individual patient. Nucleic acid–based
technologies have enhanced the diagnosis of bacterial and viral
infections as the result of increased test sensitivity and rapid
turnaround time. In addition, knowledge of sequences that un-
derlie drug resistance allows detection of microorganisms car-
rying drug resistance genes. For example, early detection of
HIV-1 infection and strain resistance to selected antiretroviral
drugs has enabled physicians around the world to more accu-
rately diagnose and treat HIV-1 infection with the appropriate
antiretrovirals. Newer automated tests using nanotechnology
that no longer require addition of multiple reagents are being
used for point-of-care diagnosis. The number of commercially
available tests and their uses continue to increase logarithmical-
ly, and the cost of instruments and their assays continue to de-
crease. In the last 2 years, the FDA has cleared (through the 510
[k] pathway) or approved (through the premarket approval
pathway) numerous molecular diagnostic tests (Table 2).
Nucleic acid amplification methods for viral targets are on
the whole faster, more sensitive, and more cost-effective than
traditional culture methods. The diagnosis of enteroviral men-
ingitis, herpes simplex virus (HSV) encephalitis, and CMV
infections in immunocompromised patients are examples of
clinically relevant and cost-effective applications of nucleic
acid–based tests. Conventional methods are more readily re-
placed in virology than in bacteriology because the tissue
culture–based virology methods are costly and generally less
Table 2. Food and Drug Administration Microbiology Devices
Cleared Through the 510(k) Pathway or Approved Through the
Premarket Approval Pathwaya
FDACenter for Devices and Radiological Health Division
of Microbiology Devices: Devices Cleared/Approved
January 2011–February 2013
Year
510(k)
Molecular
510(k)
Serology/
Other
CLIA
Waivedb
PMA
Molecular
PMA
Serology/
Other
2013 7 2 0 0 0
2012 16 33 3 2 2
2011 17 25 6 3 9
Total 40 60 9 5 11
Abbreviations: 510(k), Section 510(k) of the Food, Drug, and Cosmetic Act;
CLIA, Clinical Laboratory Improvement Amendments; FDA, Food and Drug
Administration; PMA, premarket approval.
a FDA regulatory pathways for in vitro diagnostics (IVDs) are based on the risk
of a false-negative or false-positive result for a particular microorganism on
subsequent patient management. IVDs are grouped into 3 categories
depending on level of risk and knowledge of a particular disease state: Class I
and II analytes are regarded as having a low (I) or moderate (II) risk of harm and
require a 510(k) submission to be sent to the FDA for premarket clearance.
Class III analytes are considered to have a high or unknown risk and require
more detailed information to be submitted to the FDA in the form of a PMA
submission to determine if they are safe and effective.
b CLIA-waived assays are those that demonstrate that they are simple enough
to be run by untrained personnel in settings such as physicians’ offices and
that results obtained are similar to those generated by a high/moderate
complexity laboratory with trained technical staff.
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sensitive than newer molecular methods. Some viruses are
highly labile (eg, respiratory syncytial virus [RSV]), cannot be
routinely cultured (eg, coronaviruses), or are dangerous to
culture (eg, variola). Antiviral susceptibility testing is not rou-
tinely performed, but when it is needed, such as for the identifi-
cation of ganciclovir-resistant CMV, mutations can be rapidly
identified using nucleic acid amplification coupled with se-
quencing. In addition, FDA-cleared multiplex assays utilizing
real-time amplification methods enable the simultaneous de-
tection of multiple respiratory viruses, and research assays can
detect the nucleic acid of viruses heretofore unrecognized and/
or not cultivatable in vitro.
Beyond pathogen identification, molecular methods guide
patient management. Quantification of viral nucleic acid is
used to stage disease activity, prognosticate disease progression,
and monitor efficacy of therapy. For example, the risk of pro-
gression to AIDS and ultimately death is directly related to the
magnitude of the HIV-1 RNA level in plasma. Similarly, viral
load determines the risk of perinatal and sexual transmission.
Reduction in viral load levels is associated with increased
patient survival and decreased viral transmission. Genotyping
of selected pathogens is important for specific therapeutic pro-
tocols, especially for HCV and HIV-1. Antiviral susceptibility
testing also guides specific therapy.
Genotyping by molecular methods also has prognostic value.
For example, human papillomavirus (HPV) types 16 and 18 are
associated with high-risk progression to neoplasia, and types 6
and 11 are associated with venereal warts and a low risk of neo-
plasia. Testing for high-risk HPV DNA is an established
method for managing women with the cervical cytologic diag-
nosis of atypical squamous cells of undetermined significance.
Patients are referred for colposcopy based on the detection of
high-risk types of HPV DNA. Similarly, CMV load testing can
help distinguish between active disease and asymptomatic in-
fection, as higher levels of CMV DNA increase the risk of active
disease. Thus, CMV load measurement is useful for deciding
when to initiate preemptive therapy in organ transplant recipi-
ents. It is likely that quantitative assays will also help distinguish
disease from asymptomatic infection with other herpesviruses
such as Epstein-Barr virus and human herpesvirus 6.
Molecular methods have had a particularly significant
impact on the discovery of previously unrecognized or unculti-
vable pathogens. HCV and Tropheryma whipplei are examples
of uncultivable microorganisms first detected through molecu-
lar methods. Nucleotide sequencing analysis of the 16S bacteri-
al RNA gene is expanding our knowledge of the phylogenetic
relationships among bacteria and is frequently used for bacteri-
al identification, for assessing nosocomial and community out-
breaks, and for epidemiological surveillance. Pyrosequencing
or ultradeep sequencing enables the detection of multiple
strains of HIV-1 within a single individual and identification of
minority mutants in the quasispecies. Similarly, pyrosequenc-
ing is used to classify mycobacteria and nocardia into clini-
cally important groups and to identify yeast and filamentous
fungi.
Use of Diagnostics Beyond Individual Patient Management
Infectious diseases are closely dependent on the nature and
complexity of human behavior, as they reflect who we are, what
we do, and how we interact with other people, animals, and the
environment. More recent changes in the global climate and
environmental changes from hurricanes, flooding, and earth-
quakes have dramatic influence on the frequency of certain dis-
eases in new locations such as postearthquake cholera in Haiti,
the expansion of dengue into North America, or dysentery in
Pakistan after floods. Minute or dramatic changes in the envi-
ronment can have significant impact on the spread of mosqui-
toes and other disease vectors, resulting in resurgence of diseases
such as malaria and dengue. Diagnostics are critical tools in
keeping up with continuously changing disease dynamics, and
have many applications beyond individual patient management.
The use of infectious diseases diagnostics includes epidemio-
logic surveillance, infection control efforts, antimicrobial stew-
ardship, facilitation of clinical trial enrollment, companion
diagnostics, and other codevelopment of drugs and diagnostic
tests. In the case of epidemiologic surveillance, genetic detec-
tion of rifampin resistance in M. tuberculosis is used as a
marker for multidrug resistance, enabling public health officials
to estimate the extent of the disease within selected populations
and to optimize antimycobacterial therapy.
Antimicrobial stewardship, or the optimization of antimicro-
bial use in clinical settings, is enhanced by assays that can
detect antimicrobial resistance genes. For example, molecular
assays can detect the presence of methicillin resistance genes in
Staphylococcus aureus isolates, or extended-spectrum β-lactamase
or carbapenemase resistance genes in gram-negative bacilli. Sur-
veillance for penicillinase-producing and/or fluoroquinolone-
resistantNeisseria gonorrhoeae can be achieved with new assays.
Pulsed-field gel electrophoresis, repetitive sequence–based PCR
(rep-PCR), and, increasingly, whole genome sequencing are
used to characterize outbreaks of disease in multiple healthcare
settings.
A new generation of antimicrobial and antiviral agents high-
lights the need for diagnostic tests to identify the subpopula-
tions of patients who will benefit from therapy. A classic
example is the detection of CCR5 and CXCR4 tropism of HIV-
1 when using an antiretroviral drug such as maraviroc, which
competitively binds to CCR5 on CD4+ T cells. The presence of
a CXCR4 tropic virus strain dramatically lowers the effective-
ness of the drug. Hence, use of maraviroc and other entry in-
hibitors is encouraged by the FDA only in individuals who
have been identified with the CCR5 HIV tropism.
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Increased Use of Point-of-Care and Near-Patient Tests
FDA-cleared multiplex PCR platforms are designed to probe re-
spiratory specimens, stool samples, and positive blood culture
bottles for an array of pertinent pathogens. Many of these tests
are classified as “moderately complex” or “waived” under CLIA
regulations. In addition to FDA approval or clearance of new di-
agnostic tests, CMS regulates the conduct of diagnostic testing in
the United States through CLIA. Tests are categorized according
to their complexity, with differing requirements for personnel
expertise, documentation, and oversight. Simple, low-risk tests
can be “waived” and performed in physicians’ offices and other
locations without routine regulatory oversight. With appropriate
training, waived or moderately complex tests can be performed
by laboratory assistants or other healthcare personnel (such as
nurses or clinical personnel) on instruments located outside the
central laboratory (eg, rapid response laboratories adjacent to
emergency rooms or in large physician office buildings). Results
are available within 1–2 hours and hence can inform critical
patient management decisions: for example, whether to initiate
antiviral therapy for influenza, begin therapy for tuberculosis, or
initiate antibiotic prophylaxis for pregnant women for carriage
of group B streptococci, or whether a higher level of care (ie, out-
patient to inpatient settings) may be appropriate.
Future of Infectious Diseases Diagnostics
Whereas there have been significant recent advances in the
field of clinical microbiology, and increased availability of mo-
lecular and other diagnostic tests, the tests are still not optimal-
ly integrated into clinical care for the benefit of patients. Is this
because available tests do not address priority clinical needs?
Are healthcare providers inadequately informed about the
availability and utility of many tests? Are there barriers to the
research, development, and regulatory approval of the most
needed diagnostics? What are the challenges to laboratory adop-
tion and integration of diagnostics into diverse healthcare set-
tings? In the rest of this paper, we investigate these questions and
offer recommendations to address the identified challenges.
SECTION II: UNMET DIAGNOSTIC NEEDS IN
THE CLINICAL SETTING
Prompt initiation of appropriate antimicrobial therapy has led
to dramatic reductions in infection-associated morbidity and
mortality. However, antibiotic overuse may cause considerable
harm as a result of unintended drug toxicity, the development
of resistance, and Clostridium difficile infection. Diagnostic
tests have the potential to improve patient care when the results
are available to clinicians in a meaningful time frame, are reli-
able enough to influence pathogen-directed treatment deci-
sions, and provide important epidemiologic information. Here
we summarize the unmet diagnostic needs for infectious
diseases, and describe the basic elements that are required for
tests to have clinical impact using a variety of healthcare set-
tings, disease states, public health activities, and patient popula-
tions as illustrative examples.
The Outpatient Clinic
Patients in the outpatient clinic setting are most often not seri-
ously ill, but may have an infection that would benefit from an-
timicrobial therapy. Overuse of antibiotics, however, is a
significant problem among outpatients. For example, several
studies document that 50% or more of adult and pediatric out-
patients who present with acute upper respiratory tract infec-
tions receive antibiotics [1–3], despite the fact that the majority
of these illnesses are caused by viruses. Antibiotic prescribing
in these situations is partly due to the inability to exclude a bac-
terial infection or to identify a viral pathogen quickly.
Unmet diagnostic needs in the outpatient clinic thus include
the development of tests that can accurately rule in or out a bac-
terial infection (eg, biomarkers that distinguish viral vs bacterial
pneumonia) with sufficient certainty that antibiotics can be
avoided. Application of POC testing that can reliably detect
viral and/or bacterial pathogens would result in enhanced care,
less antibiotic empiricism and, at least in theory, reduced patient
and societal cost of illness. Accurate tests to detect infection
with a single common pathogen, such as influenza, that can be
used to direct downstream patient management are also useful
in the outpatient setting. Pediatric studies in particular have
shown decreased use of antibiotics and increased use of antivi-
rals when influenza is diagnosed by rapid testing [4–7]. Similar
results have been shown for group A streptococcus [8]. Unfor-
tunately, the most widely utilized POC diagnostics are rapid
antigen tests, which often have limitations in sensitivity [9, 10].
To impact clinical management decisions, test results are
needed within roughly 1 hour. The short time frame would be
met by a CLIA-waived test performed by the physician, the
medical assistant, or an immediately contiguous rapid response
laboratory. Few tests are currently available that meet these cri-
teria. Fully automated molecular technologies with high sensi-
tivity and specificity (eg, for respiratory tract infection) are
currently either too expensive, time consuming, and/or not of
low enough complexity for routine use in the clinic. It is antici-
pated, however, that the price of fully automated molecular
platforms will decrease as a result of manufacturing advances
and free market competition.
The Emergency Department
Physicians in the emergency department (ED) face many of the
same issues as outpatient physicians, but work within a differ-
ent framework and with a different set of resources at their dis-
posal. ED physicians are often managing patients who are sicker,
and with whom they do not have an ongoing relationship or
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means for follow-up. Infectious diseases decision making in the
ED revolves around empiric antimicrobial prescribing, the
extent of testing, and whether the patient’s illness requires
further care in a general hospital bed or in the ICU.
The diagnosis and management of community-acquired
pneumonia (CAP) illustrates the need for rapid results (ie, test
results that are available to the clinician during the ED encoun-
ter) and tests with high enough prognostic value to allow safe
outpatient discharge versus hospital admission. Microbiologic
testing for an etiologic diagnosis in CAP is presented as “con-
troversial” in the 2007 IDSA/American Thoracic Society (ATS)
guidelines, because at the time, the literature indicated a low di-
agnostic yield with traditional culture and sensitivity and hence
minimal impact on clinical care [11]. The IDSA/ATS recom-
mendation calls for improvements in diagnostic capabilities, as
the symptoms of bacterial CAP overlap with viral causes of
pneumonia as well as exacerbations of asthma or chronic ob-
structive pulmonary disease. In addition, Medicare perfor-
mance measures require that appropriate empiric therapy be
selected for CAP in the ED.
The FDA clearance of competing multiplex platforms signals
a dramatic increase in the power to detect pathogens in the
airway, with panels containing up to 17 viral analytes and 4 or
more bacterial analytes. The prospect for reduced empiric anti-
biotic use is evolving rapidly. Literature over the last several
decades indicates identification of the etiology of CAP in only
20% of patients; at least 1 Scandinavian study, using modern
methods, increased that percentage to 89% [12]. The problem
now is that current panels detect only atypical bacteria (eg,My-
coplasma pneumoniae and Chlamydophila pneumoniae) and
not typical bacterial pathogens such as Haemophilus influenzae
and S. pneumoniae. The challenge with these typical bacteria
and some viral pathogens is the need to determine if the
identified pathogen is colonizing or invading. Hence, there is
increased interest in biomarkers; procalcitonin (PCT) is a
promising biomarker that can be used in addition to fever, leu-
kocytosis, and clinical syndrome as a predictor of bacterial
infection.
As opposed to the outpatient clinic setting, most EDs are
associated with inpatient facilities. Therefore, diagnostic tests
ordered from the ED can be more complex and do not neces-
sarily require a CLIA waiver to meet the need for rapid
turnaround time. Many hospitals are now developing “rapid-
response” sections within the clinical laboratories that are
located near the patient and staffed for selected testing 24 hours
a day, 7 days a week. These laboratories can be structured to
perform fully automated molecular testing [13] and/or PCT
testing. In addition, many EDs have adopted CLIA-waived
PCT testing, urine dipstick testing, and pregnancy testing that
is performed by ancillary staff in the ED at the time of the
patient visit. Turnaround time is critical for tests conducted in
the ED that are used to make prescribing decisions for patients
who are ultimately discharged, or to determine the need for a
higher level of care (such as ICU admission, or contact or respi-
ratory isolation), with diagnostic tests ideally providing results
within an hour.
The Hospital Ward and Intensive Care Unit
Physicians working in the inpatient setting are faced with in-
creasingly complicated diagnostic dilemmas. Even in the most
state-of-the-art hospital facilities, there are multiple high-acuity
diseases for which current infectious diseases diagnostics fall
short, and we examine 3 key disease areas.
Central Nervous System Infection
The diagnosis of meningoencephalitis can be challenging
because the differential diagnosis is often extensive and in-
cludes infectious, postinfectious, and noninfectious causes. Ad-
ditionally, routine culture methods are slow and the recovery of
viable microbes may be diminished by prior receipt of antibiot-
ics. More sensitive molecular-based assays for the detection of
viral pathogens directly in CSF have been developed, but cur-
rently the only FDA-cleared tests are for enteroviruses.
The potential benefits of rapid NAAT are perhaps best exem-
plified by clinical studies of HSV encephalitis in adults and en-
terovirus meningitis in children. PCR testing on CSF is as
sensitive as brain biopsy for the diagnosis of HSV encephali-
tis [14]. Timely access to enterovirus reverse transcription PCR
(RT-PCR) results facilitates shorter hospital stays, reduces anti-
biotic use, and lessens ancillary laboratory testing [15].
Despite comprehensive evaluations with a variety of different
laboratory tests including serology, culture-based methods, and
currently available molecular assays, as many as 62% of patients
with encephalitis remain undiagnosed [16]. New tests for the
diagnosis of acute and chronic CNS infections are clearly
needed. Given the breadth of pathogens implicated in CNS
disease, more comprehensive molecular panels for the agents of
meningoencephalitis, both in the immunocompetent as well as
the immunocompromised host, would bring added value to
commercially available tests. In addition, the impact that these
assays have on patient outcomes and the overall cost of hospital
care are required to justify their routine use.
Sepsis
Acute organ dysfunction secondary to infection is a medical
emergency with increasing incidence. Like encephalitis, the di-
agnosis of sepsis may be difficult because clinical signs can
overlap with noninfectious causes of systemic inflammation
and blood culture results typically require 1–5 days to complete.
Early fluid resuscitation combined with the initiation of appro-
priate antimicrobial therapy improves outcomes [17, 18], but
the clinical parameters at the heart of the sepsis definition (ie,
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the systemic inflammatory response syndrome [SIRS]) lack
specificity toward an etiologic diagnosis. Consequently, approx-
imately 20%–30% of patients with severe sepsis receive inade-
quate empiric antimicrobial therapy [19–21]. On the other
hand, indiscriminate use of multiple antibiotics may have detri-
mental effects, such as adverse events, C. difficile infection, and
a rise in antimicrobial resistance.
Procalcitonin has been widely studied as a surrogate marker
of bacterial infection in patients with SIRS. PCT levels increase
in a variety of “shock” states—for example, bacteremic shock,
cardiogenic shock, neurogenic shock, and any condition that
causes a low flow state and perhaps allows translocation of gut
bacteria. On the other hand, 1, or preferably, 2 normal PCT
levels in the hypotensive patient virtually eliminates invasive
bacterial infection as an etiology; the negative predictive value
is >95% [22–24]. Sequential PCT levels are an excellent guide
to the duration of antibacterial therapy [25, 26], but a better un-
derstanding of how PCT functions within the broader innate
immune response and correlations with microbial etiology are
still needed. Furthermore, a highly sensitive test (ie, negative
predictive value of >99.9%) would be required to confidently
withhold broad-spectrum antibiotics from a critically ill patient
with systemic signs of infection. Research is ongoing to identify
new biomarkers or combinations of markers that distinguish
SIRS related to infection. In addition, host gene expression pro-
filing using peripheral blood mononuclear cells suggests that
distinct “biosignatures” can be used to differentiate gram-posi-
tive from gram-negative infections as well as viral from bacteri-
al or fungal processes [27]. Proteomic patterns are similarly
being assessed for their diagnostic potential. The challenge now
is to conduct clinical studies to identify and validate these diag-
nostic and/or prognostic signatures.
Ultimately, pathogen-specific tests are needed to guide anti-
microbial management in septic patients. FDA-cleared multi-
plex PCR panels are available to identify a small number of
microorganisms in positive blood culture bottles within a few
hours as opposed to the several days usually required. Molecu-
lar diagnostics that detect microbial DNA directly in blood
have achieved a modest level of success, but several limitations
still exist. Studies of pan-bacterial PCR, for example, have been
confounded by the presence of pathogen DNA contamination
introduced at the time of specimen collection and/or prepara-
tion [28], and the turnaround time to results is lengthened by
the need for DNA sequencing following nucleic acid amplifica-
tion. A multiplex PCR panel, designed to directly detect and
identify 25 of the most common bacterial and fungal causes of
bloodstream infection within several hours, has been devel-
oped. Positive agreement between the commercial PCR and
blood culture has ranged from 55% to 85% in nonneutropenic
patients [29–35], illustrating that current molecular assays remain
relatively insensitive compared to blood culture. Furthermore,
the clinical significance of specimens positive only by PCR,
with negative cultures for the same organism at other body
sites, remains difficult to interpret, as standard NAAT testing
does not differentiate viable from nonviable organisms. Multi-
center clinical trials are necessary to define the diagnostic accu-
racy of molecular assays performed on blood, and more
sensitive approaches are obviously needed. Based on available
data, well-designed multiplex PCRs appear to have value as
sepsis diagnostics when used in conjunction with conventional
culture and routine antibiotic susceptibility testing.
Looking forward, a diagnostic strategy that incorporates sen-
sitive biomarkers (eg, infection present yes/no) followed by
pathogen-specific tests that are linked to a rapid assessment of
drug resistance could revolutionize sepsis management. Timely
reporting of key drug resistance determinants, such as the
mecA gene associated with S. aureus methicillin resistance or
the blaKPC carbapenemase harbored by some Klebsiella pneu-
moniae and Escherichia coli isolates, is essential for optimum
impact on antimicrobial selection and infection control practic-
es. Backup in vitro susceptibility testing would still be necessary
to verify that the resistance gene(s) was functional.
Hospital-Acquired and Ventilator-Associated Pneumonia
Healthcare-associated pneumonia (HCAP), including hospital-
acquired pneumonia (HAP) and ventilator-associated pneumo-
nia (VAP), are common healthcare-associated infections that
manifest high morbidity and mortality. HCAP, HAP, and VAP
are caused by a wide variety of mostly bacterial pathogens and
may be polymicrobial. The frequency of specific multidrug-re-
sistant pathogens is likely to vary across institutions and differ-
ent patient populations, thus emphasizing the need for local
surveillance data.
Current HCAP guidelines recommend immediate empiric
therapy because treatment delays affect mortality and a defini-
tive diagnosis can be difficult [36]. This approach likely leads to
overtreatment of many noninfectious processes that mimic
pneumonia. Alternatively, management strategies predicated
on microbiology are associated with less antibiotic usage in
ICU patients and have the potential to improve patient out-
comes [37, 38]. Lower respiratory tract specimens (eg, tracheal
aspirate, bronchoalveolar lavage, or protected brush) are pre-
ferred for making a microbiologic diagnosis of HAP or VAP,
but invasive sampling may not always be possible. Furthermore,
positive Gram stain or culture from the lower respiratory
tract does not always distinguish an invasive pathogen from
airway colonization. Quantitative cultures of lower respiratory
tract specimens have been advocated to improve diagnostic
specificity; however, a recent Cochrane review concluded that
quantitation did not improve outcomes for intubated pat-
ients as compared to those managed with qualitative results
only [39].
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Respiratory specimens are amenable to rapid molecular test-
ing, yet there are currently no commercially available pathogen-
specific assays for HAP or VAP, although off-label studies have
shown some success for detection of S. aureus infections [40].
Like sepsis, future assay development should also include simul-
taneous assessment of key drug resistance genes. To separate
commensals and asymptomatic colonizers from overt pathogens
in patients with fever, leukocytosis, and pulmonary infiltrates,
quantitativemolecularresultsmayprovetobeuseful,unlikequan-
titative cultures. In addition, novel approaches, such as detec-
tion of specific virulence determinants, are needed.
Infection Control and Hospital Epidemiology
The hospital epidemiologist and infection preventionist deal
with issues ranging from isolation of patients with transmissible
infections to outbreak investigation. Unmet diagnostic needs in
this arena primarily relate to rapid identification of hospitalized
patients with a contagious illness or drug-resistant pathogen,
and rapid typing of organisms to determine epidemiologic
linkage.
Rapid identification of antibiotic resistance is central to
timely isolation of patients harboring drug-resistant organisms.
Rapid tests have been FDA cleared for methicillin-resistant
Staphylococcus aureus (MRSA) screening and vanA-containing
vancomycin-resistant enterococci (VRE), and new assays are
now available for the rapid detection of MRSA and VRE from
positive blood culture bottles. Gram-negative resistance is
highly complex, and tests to identify organisms that produce
extended-spectrum β-lactamases and carbapenemases are re-
cently available or on the horizon.
A recent issue in hospital epidemiology and infection
control, one that has been particularly prominent in pediatrics,
is isolation of patients testing positive for respiratory pathogens
by PCR. The increased sensitivity of PCR and the introduction
of large pathogen panels have significantly increased the
number of hospitalized patients in respiratory isolation. But is
this necessary, particularly in the case of rhinovirus, for which
shedding can be prolonged [41] and detection is common
among healthy persons [42]? Understanding which children
require isolation is an important unanswered question. Addi-
tionally, determining whether PCR-based detection indicates
active infection and transmissibility, when postexposure pro-
phylaxis is necessary, and which pathogen is primary in a dual
detection is important both clinically and for cohorting purpos-
es. Bordetella pertussis detection by PCR has raised all of these
issues, and recent outbreaks have highlighted the need for a sol-
ution. Quantitative PCR may be helpful in this regard but will
need additional study.
Prompt outbreak identification is central to controlling the
spread of disease, but recognizing that an outbreak has oc-
curred can be difficult. Most typing methods to detect organism
relatedness require that specimens be sent to reference
laboratories, with confirmation of an outbreak possibly requir-
ing days to weeks. Rapid methods to determine relatedness
between organism isolates that could be performed by the hos-
pital microbiology laboratory would improve outbreak detec-
tion. One commercial system, based on analysis of repetitive
elements, is available for bacterial strain typing, but it has a
number of limitations and is not widely used.
Public Health Surveillance
Public health surveillance monitors infectious diseases in the
community in order to identify their occurrence and trends so
that measures can be identified to control them and prevent
them from reappearing. Examples include identification of re-
surgence in vaccine-preventable diseases, detection of food-
borne illness outbreaks, and monitoring the emergence of
antimicrobial-resistant organisms. Testing to support surveil-
lance activities may occur in clinical laboratories but is often
conducted and/or confirmed in public health laboratories and
the CDC.
For public health surveillance, tests must provide sufficient
information to distinguish among strains or serotypes and
perhaps identify virulence characteristics and susceptibility to
antimicrobial agents, a more detailed characterization than
clinical laboratories may require. Although public health labo-
ratories are preparing for a transition to novel technologies,
currently they rely on cultured organisms to support such char-
acterization. For example, PulseNet enables the detection of
foodborne outbreaks through the characterization of DNA fin-
gerprints using pulsed-field gel electrophoresis. Isolates with in-
distinguishable DNA patterns can be identified, thus linking
patients and, ultimately, the source of the infection.
As culture-independent technologies become predominant
on the clinical front lines, strategies for specimen preservation
and partnerships with clinical laboratories for specimen collec-
tion will be critical. One approach may be to ask developers of
new technologies to propose a “public health plan” at the time
of their submission for product approval. Whereas preserving
organism-based surveillance capabilities is an important short-
to medium-term necessity for public health, development of al-
ternative surveillance strategies is a crucial long-term goal. Mo-
lecular strategies such as whole genome sequencing are under
consideration, but will take significant bioinformatics capabili-
ties, and time to build databases that can replace those built
up over many years using older technologies. It will also be es-
sential to ensure that laboratories are providing standardized
information for surveillance purposes. The CDC has recently
proposed a new initiative, theAMD initiative, designed to improve
its genomic sequencing and bioinformatics capabilities, which
will be important for public health surveillance using these new
technologies.
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Biodefense and Emerging Infectious Diseases
Diagnostics for biodefense-related pathogens offer unique chal-
lenges in both their development and utilization. Perhaps the
greatest impediment to development lies in the limited avail-
ability of clinical specimens that are typically required as part of
the traditional regulatory submission process. Insufficient
quantities of appropriate samples have been partially addressed
by allowing an alternative methodology, the use of spiked speci-
mens that mimic the clinical specimens that are expected to be
encountered. This paradigm may also prove valuable in the
setting of an emerging infectious disease for which a new assay
must be rapidly developed, as in the recent case of the novel
Middle East respiratory syndrome coronavirus (MERS-CoV).
Other relevant issues concern prompt diagnostics implementa-
tion, likely to be required in mass casualty situations. Thus,
high throughput, field portability, and minimal training, both
in operation and interpretation, will be paramount features of
such novel assays. Finally, because these assays will not be in
routine use, the development of stand-alone assays, with neces-
sary long-term storage and continual replenishment of equip-
ment and reagents, would be costly. As a result, the development
and adaptation of existing multiplexed platforms in routine use
for more common infectious diseases is likely to be pursued to
provide a robust capability if and when a need should arise.
Current regulations allow for the development and deploy-
ment of diagnostic assays in the case of a public health emer-
gency through an Emergency Use Authorization (EUA). Use of
the EUA had its first real test during the 2009 influenza
A(H1N1) pandemic (A[H1N1]pdm09). The CDC developed a
PCR assay and the FDA cleared its use under the EUA, allow-
ing for rapid development and deployment of an assay to
detect the A(H1N1)pdm09 strain to the public health laborato-
ries. This was followed by the development of a number of
commercial assays that were also cleared through the EUA for
use in routine clinical laboratories. The EUA mechanism was
utilized again in April 2013, as the CDC developed and the
FDA cleared a diagnostic test for the emerging influenza A
(H7N9) strain. Similarly in June 2013, the FDA worked with
the CDC to authorize its assay for MERS-CoV, which was de-
clared a potential threat to public health at the end of May. The
regulatory hurdles that might normally hinder such rapid de-
velopment can be overcome through the EUA mechanism
during a declared emergency or declared potential high risk for
an emergency.
Resource-Constrained Settings
Diagnostic implementation and utilization in resource limiting
and/or constrained settings present unique challenges relative
to traditional secondary and tertiary care settings. Although
sensitivity and specificity are considerations regardless of setting,
differences in prevalence of disease and the potential for a
larger differential diagnosis may render predictive values less
clinically useful in particular applications. In terms of signifi-
cant resource limitations, desirable diagnostic assays should
require little to no power input (such as electricity) as well as
minimal technical skill and training in both the operation and
interpretation of the test. Portability should be high and storage
requirements for specimens and reagents (such as cold chain)
should be minimal. The instruments should be able to with-
stand temperature extremes and power surges (if electricity is
required). Finally, the interval from sample collection to a clini-
cal decision-making result must occur during a single visit. A
novel rapid test for diagnosis of drug-resistant tuberculosis,
rapid antigen testing for malaria, and a novel rapid test for
early diagnosis of leprosy are examples of emerging technolo-
gies with applications in the developing world. It should be
noted that resource-constrained settings can occur within de-
veloped countries, such as underserved inner-city and rural
areas. While the issues described here are relevant for less de-
veloped environments, all of these attributes are also appropri-
ate for medical office practices, public health clinics, and field
operations. In fact, the development of technology suitable for
diagnostic assays for resource-limited countries, as in the case
of tuberculosis or malaria, may create opportunities for novel
applications in countries with more abundant resources.
Special Patient Populations
Immunocompromised Hosts
The diagnosis of severe infection in immunocompromised
patients also presents unique diagnostic challenges. Immuno-
suppressed patients may have minimal or atypical signs of in-
fection, and invasive testing may not be possible due to
coagulopathy or severe illness. Minimally invasive approaches
that are predicated on the host response to infection, however,
are unlikely to be effective in the face of neutropenia and/or im-
munosuppressive therapy. In addition, the breadth of potential
pathogens affecting the immunocompromised greatly exceeds
that of other patient populations. The creation of diagnostic
panels that target an even broader range of organisms is re-
quired for optimal patient care.
Diagnosing invasive fungal infection is particularly problem-
atic due to the insensitivity of classical culture and microscopy
combined with the moderate predictive value of current fungal
biomarkers. Diagnostic uncertainty unnecessarily delays initia-
tion of appropriate antifungal therapy, which is in turn linked
to poor outcomes for a variety of invasive fungal infections.
Different amplification-based strategies have been evaluated for
the diagnosis of invasive Candida and Aspergillus infections in
high-risk hematology patients with varying results. Recent
meta-analyses highlight the lack of assay standardization com-
bined with inconsistent testing algorithms as sources of hetero-
geneity across studies [43, 44]. New options for the diagnosis of
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a variety of emerging fungal diseases in addition to Candida
and Aspergillus are urgently needed, and test development
should be paired with robust laboratory standardization efforts
akin to the European Aspergillus PCR Initiative [45].
Children and Adolescents
Pediatric patients are seen in all of the clinical settings previ-
ously discussed, and their general diagnostic needs are
similar. However, pediatric patients have several unique needs
that should be specifically addressed. An overarching unmet
need is validation of tests within pediatric populations. Due to
the enhanced costs associated with obtaining FDA clearance or
approval for a new diagnostic product specifically in children—
because of the large numbers of children in various age groups
that need to be enrolled, difficulty in obtaining informed
consent, and inability to get adequate amounts of specimens
for testing—most diagnostics are vetted only for adult patients,
with results assumed to be similar for children, which is not
always true. For example, biomarker-based testing such as PCT
needs specific reference ranges for young infants [46]. Pathogen-
based testing also needs to take into account colonization rates
in children; this is true for urinary antigen testing for pneumo-
coccal disease, a test that has a poor positive predictive value in
children due to their high pneumococcal colonization rates [47].
Finally, C. difficile testing is of questionable utility in children
<2 years of age as asymptomatic carriage of toxigenic strains is
common [48].
Additional needs unique to pediatrics include the need for
smaller sample volumes, as blood volumes required for testing
often cannot be obtained safely from young or premature
infants. A term newborn has approximately 300 mL of total
blood volume and premature infants can have significantly less.
Testing validated for less invasive clinical samples is also desired,
although this is not exclusive to pediatrics. Invasive procedures
can be more difficult to perform in children and there is a reluc-
tance to put children through an invasive test. Last, pediatrics is
almost always a smaller diagnostic market than that for adult
testing and there is often little incentive for test validation in chil-
dren. As with therapeutics, additional incentives should be pro-
vided for pediatric diagnostic validations and FDA clearance.
Communication and Utilization of Results
As new testing methodologies are introduced into the clinical
laboratory, particularly assays for which timeliness is essential
to changing clinical practice, an important hurdle to address is
how to quickly communicate the rapid results to the appropri-
ate care provider, and when appropriate, to public health au-
thorities. In studies investigating the utility of a rapid test to
identify MRSA versus methicillin-susceptible S. aureus (MSSA)
and coagulase-negative staphylococci from positive blood cul-
tures, improvements in antibiotic management and mortality
were contingent upon rapid result communication directly to
the treating physician or a designee such as an infectious dis-
eases–trained pharmacist or member of the antibiotic steward-
ship team [49]. Given the financial constraints and staffing
limitations faced by many laboratories, it is essential that an ef-
ficient means of communication be developed that does not
involve manual phone calls. Communication through an inter-
mediary such as a pharmacist, infectious diseases consultant, or
the antibiotic stewardship team may be ideal because guidance
about appropriate therapy and infection control measures can
also be provided on a case-by-case basis. Information technology
services, such as delivery of results to mobile devices, are also re-
quired to provide electronic communications support for the ef-
fective, and preferably automated, transmission of laboratory
results such that the benefits of rapid testing can be fully realized.
SECTION III: NEWANDDEVELOPING
TECHNOLOGIES: IMPACTONUNMETCLINICAL
NEEDS
During the last decade, new diagnostic technologies and testing
platforms revolutionized the way in which laboratories identify
the agents of a wide range of infectious diseases and genetic
markers related to antimicrobial resistance. The advances will
continue to accelerate in the near future. These technologies rely
on a variety of established and novel applications to detect nucleic
acids and/or proteins, from the pathogen and/or the host. These
advances provide laboratories with the ability to greatly improve
testing services through methods that are often more sensitive,
more specific, faster, and, depending on the target, can offer a
broader range of pathogen detection as compared to most tradi-
tional methods. Automation, including platforms that provide
simple sample-in-result-out on-demand testing, allows laborato-
ries of every size to implement “cutting-edge” technology. Impor-
tantly, these technological advances are demonstrating significant
impact on the practice of medicine, including not only a rapid di-
agnosis, but decreased length of stay, optimization of treatment
selection and antimicrobial stewardship, enhanced infectious
disease surveillance, and initiation of infection control prac-
tices [50–57].Many of these emerging technologies have potential
to address current unmet clinical needs, as outlined in Table 3
and further illustrated in the rest of the section.
Evolving Changes in Test Services and Methods
Shift From Centralized to Decentralized Point-of-Care
Testing
Although the majority of testing for infectious diseases is labo-
ratory based, POC rapid antigen-based tests have been widely
used. However, FDA-approved rapid antigen tests are only
available for select pathogens (eg, adenovirus, rotavirus, influenza
A, influenza B, RSV, L. pneumophila serotype 1, S. pneumoniae,
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S. pyogenes, Plasmodium species, C. difficile, Cryptosporidium,
Giardia, Cryptococcus neoformans, H. capsulatum, and other
fungi). The performance of such devices ranges from good (eg,
80%–85% sensitive for RSV in children <5 years of age) to poor
(eg, 30%–50% sensitive for influenza B in geriatric patients).
Results depend on the analyte, sensitivity of the test, type of
sample collected, age of the patient, and time of testing after
onset of clinical symptoms. Clinicians are not always aware of
the performance limitations of each test, and, when clinically
indicated, the need to perform additional testing.
As a result of reduced sensitivity, specificity, and limited
number of analytes detected, the current evolution is to replace
rapid antigen POC tests with commercial platforms that
perform real-time amplification and detection assays for nu-
merous pathogens. Single-step, cartridge-based molecular test
devices target pathogens pertinent to clinical syndromes (eg, re-
spiratory tract infections, CNS infections, gastroenteritis, and
sepsis). These assays can be performed on-demand, require
minimal hands-on time (1–2 minutes), require minimal techni-
cal skills to operate, and provide rapid results (20 minutes to 5
hours). However, a limitation of some cartridge-based plat-
forms is throughput capability. Some systems only allow 1 test
to be performed at a time, often requiring multiple expensive
separate platforms or additional modules. Until there is an
FDA CLIA-waived molecular POC bedside test, self-contained
multiplex amplification platforms can be located in central/
referral clinical laboratories, rapid response laboratories, and
CLIA-certified mini-laboratories in clinic and public health fa-
cilities, while still providing a result within the needed time
frame. Ideally, future POC tests will be designed such that
testing is performed with portable handheld, rechargeable or
battery operated, rapid cycling devices.
Shift From Single-Analyte Testing to Multiplex Testing
With the exception of the tests for the detection of Chlamydia
trachomatis and N. gonorrhoeae, the majority of the older mo-
lecular diagnostic assays were developed as single-analyte tests.
Today, molecular diagnostic testing has moved toward a more
broad syndromic screening approach. This trend is the result of
sophisticated technologies that enable the detection of >1
analyte at a time. Tests/devices vary from low multiplex (2–5
analytes) to 25 or more different analytes, often now combining
a mixture of pathogen types, (eg, bacteria, viruses, and para-
sites), and also antibiotic resistance markers. New highly multi-
plexed cartridge-based systems can detect the majority of
bacterial pathogens that cause community, ventilator-associated,
and hospital-acquired pneumonia within 1–2 hours. In addi-
tion, these systems can detect >20 antibiotic resistance genetic
markers. The intent is not to replace culture, as additional char-
acterization of isolates still needs to be performed on cultured
samples, but to provide a POC early diagnosis that can lead
to more focused appropriate antimicrobial therapy. Other
Table 3. Potential of New Technologies to Address Unmet Clinical Needs
Unmet Need Example of Pathogen/Syndrome Potential Technologies
Rapid testing from clinical
specimen (≤60 minutes)
HSV-1/2, VZV, enterovirus, parechovirus,
influenza, RSV, bacterial resistance (KPC,
NDM-1)
Single-step molecular cartridge-based tests
Rapid testing from clinical
isolate (≤60 minutes)
Bacterial, fungal, or mycobacterial isolate MALDI-TOFMS, single-step molecular cartridge-based tests
POC or near-patient testing
(≤60 minutes)
Respiratory infections (viral and bacterial),
meningitis
Single-step molecular cartridge-based tests, handheld devices
for molecular testing, LAMP coupled with Biosensors
Simplicity (CLIAwaived) Influenza, tuberculosis, malaria Handheld devices for molecular testing, single-step molecular
cartridge-based tests
Syndromic testing Sepsis, pneumonia (HAP, VAP, CAP),
meningitis, diarrheal diseases
Highly multiplexed single-step molecular cartridge-based tests,
PCR coupled with T2 magnetic resonance
Screening for infection Biomarkers to distinguish infection from no
infection, bacterial from viral infection
Biosensors, biomarkers
Resource-constrained
settings
HIV-1, tuberculosis, malaria Handheld devices for molecular testing, single-step molecular
cartridge-based tests
Infection control/hospital
epidemiology
Outbreak evaluations of multidrug-resistant
organism, rapid strain typing
Next-generation sequencing
Discovery of emerging
pathogens
Influenza A H5 and H7, MERS-CoV PCR coupled with ESI-TOF, next-generation sequencing
Abbreviations: CAP, community-acquired pneumonia; CLIA, Clinical Laboratory Improvement Amendments; ESI-TOF, electrospray ionization time-of-flight; HAP,
hospital-associated pneumonia; HIV-1, human immunodeficiency virus type 1; HSV-1/2, herpes simplex viruses 1 and 2; KPC, Klebsiella pneumoniae
carbapenemase; LAMP, loop-mediated amplification; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; MERS-CoV,
Middle Eastern respiratory syndrome coronavirus; NDM-1, New Delhi metallo-β-lactamase 1; PCR, polymerase chain reaction; POC, point-of-care; RSV, respiratory
syncytial virus; VAP, ventilator-associated pneumonia; VZV, varicella zoster virus.
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multiplex panels focus on pathogens found in patients with a
clinical picture of septic shock or diarrhea caused by a gastroin-
testinal pathogen. Multiplexed enteric disease panels target
common bacterial pathogens such as Salmonella, Shigella, Yer-
sinia, Vibrio, and Campylobacter species, and in addition, bac-
terial toxins (eg, Shiga toxin), parasites (eg, Giardia), and
viruses (eg, norovirus). The selection of assay analytes must be
clinically relevant; more analytes is not always better and the
testing expense may not be reimbursed. At least in the near
term, multiplex amplification platforms will replace some activ-
ities (viral culture) but will supplement other testing (antibiotic
in vitro susceptibility testing).
Molecular platforms need to adapt quickly to changing
clinical environments. New pathogens are identified (eg,
MERS-CoV), variants of old pathogens emerge (eg, influenza
A[H1N1]pdm09 and H7N9), and new antibiotic resistance
mechanisms evolve (eg, K. pneumoniae carbapenemases and
New Delhi metallo-β-lactamase-1). Hence, there is a strong in-
dication for flexibility in test or instrument design. For
example, multiplex systems involve complex primer and probe
interactions during the initial or subsequent amplification and
detection steps. The addition of new primers and probes to
detect an additional target will require validation of the newly
added target and demonstration that the performance for exist-
ing targets is not affected. The revalidation of all existing
targets does not need to be undertaken again, and the experi-
mental evidence required demonstrating performance is
limited to key points that can be addressed through in-house
studies. Furthermore, FDA encourages assay developers to
archive specimens used during the clinical evaluation for future
use, especially in cases where the multiplex panel is being ex-
panded. These ideas can and have been applied to existing
cleared multiplex devices to address detection of emerging and
evolving pathogens; however, it is important to note that these
mechanisms should not be used to inflate the assay menu of a
device to increase marketability, but rather should be used to
address true public health needs.
Nucleic Acid–Based Testing Options
Amplification-Based Technologies
To test for the presence of nucleic acid targets in clinical
samples, it is necessary to extract the nucleic acids from the
pathogen, amplify the genetic target, and then detect the ampli-
fied sequences. Traditional labor intensive nucleic acid isolation
and purification methods are now replaced by automated plat-
forms or incorporated directly into 1-step cartridge-based
devices. Nucleic acid amplification technologies have evolved
from traditional and real-time PCR, to newer methods such as
loop-mediated amplification (LAMP), transcription-mediated
amplification, nucleic acid sequence-based amplification (NASBA),
and strand displacement amplification (SDA). Technologies such
as LAMP, NASBA, and SDA are isothermal and do not require ex-
pensive thermocyclers.
Real-time nucleic acid detection methods rely on fluorometric
probes, of which there are many varieties (eg, molecular beacons,
fluorescent energy transfer, TaqMan, scorpions, and locked nuc-
leic acids). Amplified targets are detected by turbidity, chemilu-
minescence, or either solid-based or liquid bead-basedmicroarrays.
In lieu of target amplification, nucleic acids are detected di-
rectly using sensitive signal amplification methods such as
branched DNA and probe amplification methods.
Electrospray Ionization Time-of-Flight Mass Spectroscopy
For electrospray ionization time-of-flight (ESI-TOF) mass spec-
troscopy, nucleic acids isolated from clinical samples are ampli-
fied with broad-range primers targeting highly conserved
genomic regions that flank sequences with variable genetic
content. Amplified nucleic acid fragments enter the ionization
chamber of an ESI-TOF mass spectrometer. Charged strands
leave the electrospray phase and are pulsed under high vacuum.
The nucleic acid strands move through the flight tube; lower
mass amplicons travel faster and reach the detector before higher
mass amplicons. Each time an amplicon is detected, the mass
spectrum increases. In general, the ESI-TOF interrogates the am-
plicon weight to determine the base compositions of comple-
mentary DNA strands frommultiple sequences. A small number
of possible base compositions are consistent with each mea-
sured mass. Base compositions of forward and reverse amplicon
strands must be complementary, reducing possibilities to a
single, unique base composition, allowing for accurate identifica-
tion of the target.
This technology has been used to identify viral respiratory
and biothreat pathogens, including novel variants of influenza.
Resistance genes and specific toxins have also been detected. A
major benefit is the ability to identify many diverse pathogens
without having to target each analyte specifically. As with all
mass spectrometry systems, the scope of pathogen detection is
dependent on the accuracy of the ESI-TOF database. Although
this technology has great promise, there are several drawbacks
with the current instruments. The process is slow, labor inten-
sive, and, for direct sample testing, would require nucleic acid
isolation and amplification to produce sufficient concentrations
of nucleic acids for detection. The current platforms are too
large and costly to be practical in a clinical laboratory. Future
systems need enhanced sensitivity so as to allow direct detec-
tion of pathogens from clinical samples. New instruments will
be significantly reduced in size, cost, and complexity.
Sequencing
For many years NAATs have been combined with tradi-
tional capillary electrophoresis sequencing or pyrosequencing
applications. Sequencing has been used for pathogen
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identification from isolates or directly from clinical specimens
such as fresh-frozen or paraffin-embedded tissue. Sequencing
can establish a microbial etiology in cases where no pathogen
was identified by traditional culture methods or due to previous
antimicrobial therapy (eg, culture-negative endocarditis). Se-
quencing can provide a genus identification for generally >90%
of the strains, and species-level identification in 65%–85% of
the isolates tested. Some isolates are either misidentified due to
high sequence similarities to other pathogens (eg, N. gonor-
rhoeae and Neisseria meningitidis using 16S RNA sequences)
or are never identified. Other concerns include incorrect se-
quences present in public databases and the high cost of access
to commercially available vetted databases. Sequencing is also
used to identify known and novel mutations relating to drug
resistance. Due to complexity and cost, this approach is gener-
ally restricted to large university laboratories and reference
laboratories.
Fueled by the human genome project and market incentives
such as XPRIZE, “next-generation sequencing” (NGS) systems
were developed and demonstrate better performance, longer
read lengths, and increased accuracy, utilizing applications that
require fewer consumables and are less labor-intensive than tra-
ditional sequencing methods. Conversely, NGS requires exten-
sive bioinformatics for data interpretation [58]. To meet the
needs for routine clinical testing, compact NGS systems have
been developed with a small footprint and fast turnaround
time. Using these systems, sequencing could replace complex
multifaceted traditional microbiological identification proce-
dures such as biochemical testing, and sequencing could detect
virulence determinants and the genetic markers of antimicrobial
resistance. Sequencing, however, may miss new and uncharac-
terized genetic elements responsible for phenotypic resistance
mechanisms. This will require companies to perform extensive
phenotypic/genotypic comparisons and may in addition require
gene expression analysis for detecting complex phenotypes (eg,
changes in porin expression related to carbapenem resistance).
Sequence data has already proved its value in tracking out-
breaks of infection due to resistant bacteria (eg, the NIH out-
break of multidrug-resistant gram-negative bacteria [55] and
the cholera outbreak in Haiti [50]). Future studies need to
address the clinical relevance of finding a fragment of nucleic
acid that may not correlate with the patient’s clinical syndrome.
Finally, NGS systems need easy, concise, low-cost data manage-
ment and interpretation software and access to well-vetted
databases. Only then will NGS systems become a primary diag-
nostics approach for infectious diseases. The development and
implementation of standardized methods that allow for data
sharing across institutions will be critical to the success of NGS
as a public health tool for outbreak detection and response and
surveillance.
Proteomics
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight
Mass Spectrometry
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) is used for many applications
in biochemistry, polymer chemistry, and proteomics. New
MALDI-TOF MS platforms can be used routinely in clinical
microbiology laboratories for the rapid identification of bacte-
ria, fungi, mycobacteria, and parasites [59, 60]. MALDI-TOF
MS testing is relatively simple and, for most bacteria, only re-
quires transferring a portion of an isolated colony onto a well
in a designated disposable or reusable target slide. Organisms
such as mycobacteria and fungi usually require an additional
pretreatment step to ensure nonviability of the organism before
manipulation and extraction of the proteins of interest. The in-
oculated well is covered with a chemical matrix, generally α-
cyano-4-hydroxycinnamic acid, dried, and the target plate is
loaded into the instrument. Vacuum is applied to the chamber
and the target slide wells are pulsed by a laser, converting the
sample into an ionic gas composed of small molecules, pep-
tides, and small proteins. In the ionization chamber, positively
charged molecules are accelerated through an electric field and
then enter the time-of-flight mass analyzer. Smaller particles
travel faster through the tube to the particle detector. The parti-
cle detector measures the flight times, which are converted into
mass/velocity values and plotted on a mass spectrogram. The
spectrogram is then compared to a validated library of spectro-
grams using proprietary algorithms specific to each manufac-
turer. Testing of calibrators and controls ensure the appropriate
performance of the MALDI-TOF MS. The time to first result is
approximately 10–20 minutes and each new subsequent result
is available within 1 minute.
The MALDI-TOF MS systems have the essential characteris-
tics for success: rapid and accurate results, minimal technical
time, and simple sample preparation. These systems are also
amenable to integration into automated platforms that can in-
oculate the MALDI-TOF MS slide and collate the MALDI-
TOF MS identification with antimicrobial susceptibility data.
The initial cost for the MALDI-TOF MS unit ranges from ap-
proximately $160 000 to $250 000, and the yearly maintenance
costs roughly $35 000 a year. However, these expenses are offset
by the low reagent cost per identification ($.10–$.50) as com-
pared to traditional microbiologic systems (approximately
$2.50–$5.00 per identification) plus savings in technical time
(about 1 minute per identification) and the clinical benefit of
providing an organism identification in about 20 minutes [57].
Currently, when a blood culture is flagged as positive for organism
growth, laboratories generally report the results of a Gram stain
and need an additional 24–48 hours or more for organism identi-
fication and susceptibility test results. Alternative technologies
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such as peptide nucleic acid fluorescence in situ hybridization
and NAAT systems can provide identification of an organism
and some susceptibility data within hours. However, these tests
are currently limited by the number of pathogens detected, cost
per test (on average $25–$75) and, for some methods, technical
time required to perform the testing. With MALDI-TOF MS,
direct identification of virtually any organism from a positive
blood culture broth is possible within 20 minutes at a cost of a
few cents. Rapid pathogen identification has a major impact on
the selection of antimicrobial therapy [61]. Preliminary studies
demonstrate that MALDI-TOF MS can also detect certain
types of antibiotic resistance mechanisms that result in struc-
tural modifications to the antibiotic [62]. For example, the hy-
drolysis of β-lactam drugs by bacterial β -lactamase enzymes
can be detected due to a mass shift in the size of the original
compound upon hydrolysis [62]. This shift occurs within hours
of exposure of the drug to the organism of interest. Resistance
detection applications of MALDI-TOF MS are in the early
stages of development. The ultimate goal is to couple rapid sus-
ceptibility testing with MALDI-TOF MS identification within
24–36 hours of receipt in the laboratory.
Recently, a new technology that combines PCR and T2 mag-
netic resonance has demonstrated that Candida species can be
detected directly from as little as 1 mL of whole blood with a
sensitivity ranging from 1 to 3 colony-forming units/mL [63].
This technology may overcome the major limitation of the cur-
rent detection assays that can only be performed once a blood
culture bottle is flagged as positive, thereby reducing detection
time from days to hours.
Biosensors
A biosensor is an analytical device comprised of 2 elements in
physical proximity: a biological recognition element able to in-
teract specifically with a target (eg, nucleic acid or protein of a
pathogen) and a transducer that is able to convert the recogni-
tion of the pathogen into a measurable signal. The biological
recognition element may be naturally occurring (eg, microor-
ganism, enzyme, antibody, antigen, nucleic acid sequence, cell
receptor), a biologically derived material (eg, recombinant anti-
bodies and antigens, aptamers, or engineered proteins), or a
biomimic (eg, synthetic catalysts, combinatorial ligands, or
imprinted polymers). The physical transducer can be optical,
electrochemical, thermometric, piezoelectric, magnetic, or
micromechanical. This interaction generates a signal (electro-
chemical, optical, acoustical, mechanical, calorimetric, or elec-
tronic) that is amplified and proportional to the concentration
of the target analytes.
Successful POC biosensor diagnostic devices will need to
combine miniaturization using, for example, microfluidics,
with simple isothermal amplification technologies such as
LAMP and robust sensing techniques. Preliminary feasibility
studies have demonstrated that integrated nucleic acid and
protein detection on an electrochemical biosensor array can be
used to detect monomicrobial or polymicrobial urinary tract
infections [64, 65]. The electrochemical-based sensing tech-
nique provided sufficient selectivity, sensitivity, and low-cost
detection of nucleic acid sequences amplified from urine. To
complement bacterial identification, a direct biosensor quanti-
fication of bacterial 16S RNAwas developed to monitor bacteri-
al growth for antibiotic susceptibility testing [66]. Additionally,
differential impedance has been used for the direct detection of
bacterial stress responses in contaminated platelet samples [67].
Low-cost power requirements, compatibility with different ma-
trices, ease of use, and interpretation are essential for clinical
applications. Ideally, biosensors would be able to detect the
target of interest without an amplification step. This would
require a means to enhance the capture of the target nucleic
acids and/or proteins with sufficient efficiency for direct detec-
tion. Alternatively, a combination of direct nucleic acid and
protein capture (pathogen or biomarker) might have the
potential to achieve this goal. Essentially, POC biosensor prop-
erties proven relevant for such things as plant disease manage-
ment are highly applicable to early detection, identification,
and quantification of human infectious agents. Detection of
patient colonization with certain pathogens allows for the initi-
ation of early treatment or infection control strategies before a
significant outbreak can occur.
Clinical Relevance
The sensitivity and timeliness of culture results are influenced
by many factors, especially for hospitalized patients with previ-
ously administered and/or concurrent antimicrobial treatment.
As more technologies are introduced, significant challenges will
be faced in interpreting the data. Among approaches that rely
upon the detection of nucleic acids directly from clinical
samples, there is sometimes uncertainty regarding the clinical
significance of the results. The nucleic acids detected may be
from nonviable organisms or from commensal (nonpathogen-
ic) or colonizing bacteria or viruses that are noncontributory to
the disease. Therefore, nucleic acid–based assays must provide
a “clinically” relevant level of sensitivity and be of sufficient
scope to detect all relevant pathogens, or in the case of many
viruses, all genotypes. An incorrect diagnosis based on the pres-
ence or absence of nucleic acids could actually obscure the de-
termination of the real pathogen.
Clinical studies that evaluated the presence of respiratory
viruses in asymptomatic patients indicate that the old doctrine,
which considered the presence of any respiratory virus clinical-
ly significant, is no longer true [68, 69]. Individuals can shed
respiratory virus without any evidence of disease (eg, adenovi-
rus). Additionally, the clinical significance of mixed viral infec-
tions is not always clear (eg, bocavirus as part of a mixed viral
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infection). In these instances, clinicians are faced with the
challenge of asking “is this colonization versus infection” or
“what pathogen(s) is responsible for the disease?” To distin-
guish colonizers and contaminants from true pathogens, and
interpret test results, close collaboration with the laboratory is
critical, including adherence to specimen collection and trans-
port guidelines, an understanding of test performance, pretest
probability of disease, and reliance on clinical judgment, in-
cluding consultation with infectious disease physicians. For
example, in the diagnosis of bloodstream infections, the detec-
tion of the nucleic acids of a coagulase-negative Staphylococcus
species in the blood of a person with a prosthetic valve and
possible endocarditis is very different than detection in an im-
munocompetent 30-year-old with community-acquired pneu-
monia. When both S. aureus and mecA gene nucleic acids are
detected in a febrile patient with appropriate risk factors, a di-
agnosis of MRSA bacteremia is clear. The answer is not so
straightforward when CMV viremia is detected in a patient
with fever in the ICU whose blood cultures are negative for bac-
teria.
Lastly, the detection of antibiotic resistance genes directly
from clinical samples is challenging, as mere presence may not
always correlate with gene expression and clinical resistance to
therapy. In addition, linkage of a resistance marker to a specific
organism is necessary to determine the relevance of a positive
result. For example, the detection of the mecA gene from a skin
infection does not necessarily mean that the patient has MRSA,
as the majority of nonpathogenic coagulase-negative Staphylo-
coccus species that colonize the skin also contain the mecA
gene. Detection of the vanB gene in rectal swabs does not nec-
essarily indicate that a patient is colonized with a vancomycin-
resistant Enterococcus species as some anaerobes, which are
part of the normal stool flora, contain the vanB gene.
Despite these limitations, molecular methods that rely on
nucleic acid amplification offer a unique advantage in the de-
tection of pathogens in specimens collected after initiation of
antimicrobial treatment; hence, there is an opportunity to dees-
calate empiric therapy (or increase the specificity of antimicro-
bial therapy). Furthermore, the disappearance of pathogen
nucleic acids can suggest that the organism is “eradicated” and
might justify shorter courses of treatment. Last, these novel mo-
lecular technologies may lead to new insights into disease path-
ogenesis by revealing previously unknown information.
Analysis and Interpretation of Novel Data
Information generated by sequencing, mass spectrometry, and
other complex tests bring their own challenges. Sequencing, for
example, provides a significant amount of data, but how the
data are interpreted, what part of the data are most important,
and how the data relate to the infectious organisms detected all
need study and clarification. How genotypic data relate to
phenotypic data may also be unknown. Complex tests may
require complex data analysis, and algorithms for analysis are
incomplete.
Data from whole-genome sequencing, arrays, and other tech-
nologies are not consistent with the data received from older
technologies. For example, whereas previously a test result may
have simply been reported as “reactive,” advanced technologies
provide much more information, which in turn necessitates
decisions about data interpretation, priorities, and reporting
formats. Links between the laboratory equipment and the labo-
ratory information management system must be designed so
that the results are clearly presented and easily understood by
the clinician.
SECTION IV: CHALLENGES TODIAGNOSTICS
RESEARCHANDDEVELOPMENT
Many diagnostic companies have been successful recently in
developing and launching novel products for rapid detection
and identification of infectious agents. These products are for-
matted either for culture confirmation (eg, identification of
gram-positive cocci in positive blood culture bottles) or for the
detection of organisms in clinical samples (eg, viruses from re-
spiratory samples or staphylococci from wounds). However, in-
vestigators and developers face several challenges that can
impede the research, development, or approval of a new
product. These may occur anywhere along the pathway from
initial concept to final licensure for commercial use in the
United States or globally.
Challenges in Product Development
In the concept phase of a potential new diagnostic product, in-
formation is collected from healthcare institutions, scientific
advisory boards, and marketing data. Then, the potential
market for the product is estimated, research and development
costs are anticipated, the costs of clinical trials and regulatory
requirements are calculated, and the potential return on invest-
ment is determined. If the return on investment is favorable,
the project proceeds to concept phase. Because the number of
target organisms in a new diagnostic product may vary from 1
to 2 dozen or more (depending on the intended use of the
product), with each additional target increasing the cost of the
assay incrementally, input from laboratory directors and clini-
cians is critical to balance clinical need versus cost and efficacy.
Recent changes in ethics guidelines and conflict of interest
rules in many academic centers and healthcare systems now
make it difficult for key opinion leaders, and those with specific
expertise in infectious diseases, to participate in company advi-
sory boards or expert panels. Service is forbidden even if the
consultant serves on his/her own time or without compensa-
tion. Thus, it is difficult for industry to gauge unmet needs in
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the laboratory and ultimately at the bedside. Although it is ap-
propriate to avoid conflicts of interest, the loss of access to key
experts is detrimental to product design and development.
The next phase is technical feasibility, which progresses as a
function of multiple factors, including creativity, availability of
materials, and freedom to operate. Creativity is not in short
supply, but intellectual property (IP) and freedom to operate (ie,
the absence of IP barriers) can limit the direction a project may
take. Exploring IP issues is beyond the scope of this paper, but
we note that IP can be a major barrier to product development.
While companies have the option to license technology owned
by others, the high cost of royalties and licensing fees, particu-
larly on some infectious disease targets, is cost prohibitive.
Challenges in Clinical Trials
The next step is beta trials and test method validation. Here
again, conflict of interest rules impact the ability of a company
to get independent validation of novel test methods in a real-
world laboratory setting. Even clinical trials to evaluate new
products under the auspices of an institutional review board
(IRB) may now be considered conflicts of interest if the labora-
tory is compensated for the work provided. When the laborato-
ries of experts become inaccessible, companies are forced to
engage laboratories lacking the specific expertise (eg, viral
culture, or extraction of RNA from clinical samples) needed for
evaluation of a new product, and must provide additional train-
ing. Finding or developing the necessary number of laborato-
ries with the appropriate expertise to process the large number
of samples needed for a clinical trial is a costly challenge, even
if samples are sent to a central laboratory, which in some cases
is not feasible. In one recent study, up to 12% of samples were
either lost or destroyed during shipment to a central laboratory.
In the 1980s, many clinical microbiology laboratories had re-
search technologists whose job it was to oversee clinical trials of
new diagnostic testing methods. Those research positions have
long been eliminated due to financial constraints, thereby making
clinical trials a burden to the existing laboratory staff. Thus, the
number of microbiology laboratories willing to take part in clini-
cal trials of new products has shrunk over the last decade, limited
even further by conflict of interest rules, institutional regulations,
and overhead costs, which now exceed 50% in some institutions,
making contracts with those places too expensive to pursue.
After identification of appropriate laboratories, companies
must then validate the accuracy of a new diagnostic test against
a gold standard or reference method that is often less sensitive
(sometimes considerably so) and in some instances less specific
than the new method. How this conflict is managed varies from
product to product. By this stage, the company has likely had
multiple interactions with the FDA, resulting in agreement on
reference methods to be used in clinical trial design. Resolution
of “truth” (ie, what constitutes a true positive result and a true
negative result) may require the participating laboratories to
run multiple commercial assays to establish a “patient infected
status,” as has been done for evaluation of NAATs for chlamyd-
ia and gonorrhea assays [70]. This strategy has been successful
in multiple product evaluations but is also very expensive.
Increasingly, bidirectional sequencing of target nucleic acids
from organisms or directly from clinical samples is used as the
ultimate arbitrator of positivity or negativity [71]. Bidirectional
sequencing requires the development and validation of addi-
tional sequencing primers and test protocols. While the cost of
nucleic acid sequencing has decreased dramatically for routine
laboratory use, the cost of “good laboratory practice certified”
(or GLP) sequencing from reputable laboratories (with Phred
scores for the sequencing data of ≥20) has almost doubled in
the last 5 years. The cost of nucleic acid sequence analysis can
add >$100 000 to the cost of a clinical trial, which may be pro-
hibitive for smaller companies.
Another challenge is access to clinical samples containing
rarely encountered pathogens. As many clinical laboratories no
longer freeze specimens containing novel or unusual organisms
for further workup, it is becoming more difficult to find, for
example, CSF samples containing the agents of viral or bacterial
meningitis, or nasal washes with novel respiratory viruses. Even
when such critical clinical samples are available, the cost of
accessing the samples has, in many cases, become prohibitive,
and some institutions may have strict IRB policies regarding
provision of samples. The availability of biorepositories of pro-
spectively collected validated clinical samples would directly
address this problem (see Appendix B).
Such prospectively archived sample repositories have been
recommended in recent reports from the Transatlantic Task
Force on Antimicrobial Resistance (TATFAR) [72] and the
Center for Health Security (formerly Center for Biosecurity) of
the University of Pittsburgh Medical Center [73] as holding po-
tential to address the challenges to diagnostics development.
However, there are challenges to successful implementation of
repositories, as acknowledged by TATFAR, including expense,
difficulty in anticipating exactly what types of specimens to
collect, and informed consent. The key issues are the costs of
maintaining thousands of samples that may or may not be
used, and that may or may not be the appropriate specimens
for a given assay in development. Variables, such as how the
samples were collected and stored, are critical factors. It will be
important to develop standardized protocols for collection and
storage in consultation with regulators.
An example of a current infectious diseases biorepository is a
contract resource from the NIAID, run by the Aspergillus
Technology Consortium, which contains prospectively collect-
ed and archived samples from at-risk subjects who develop
proven or probable invasive aspergillosis [74]. The repository
can provide companies that are developing diagnostics for
Improved Infectious Diseases Diagnostics • CID 2013:57 (Suppl 3) • S157
aspergillosis with a source of positive and negative clinical
samples. Although thousands of specimens have been collected,
to date, no new diagnostic test has been developed. A second
approach is an on-demand model where access to prospectively
collected samples is made available to companies with a dem-
onstrated product. This approach to specimen collection is a
requirement of the new NIAID Vaccine and Treatment Evalua-
tion Units, designed to facilitate early-stage development of
drugs, vaccines, and diagnostics. This model may reduce some
of the risks associated with developing a new assay.
Companies seeking regulatory approval for some novel diag-
nostic products must demonstrate, or redemonstrate, the clini-
cal utility of the product for regulatory approval. Because of the
additional clinical trials, the PMA pathway (for a new unique
product) is 10-fold more expensive than the 510(k) clearance
pathway (for a modification of a previously approved test). This
difference may exceed the presumed return on investment for a
product. Fortunately, this is primarily an issue for molecular
assays targeting viral pathogens such as HBV, HCV, HIV-1,
HPV, CMV, EBV, and the coronavirus causing severe acute re-
spiratory syndrome (SARS). Unfortunately, the extended clini-
cal trials may be cost prohibitive, even though these are
commercially viable markets. Even the commercialization of
well-established PCR assays, such as an assay for HSV to diag-
nose meningoencephalitis from CSF, is quite difficult in the
current regulatory environment, given the paucity of samples
available, the lack of a predicate device, and the need to demon-
strate positive outcomes for the testing algorithm.
Following FDA approval or clearance of a new assay, compa-
nies must be able to manufacture all the components of the assay
(including collection and transport devices, instruments, re-
agents, and disposables) under good manufacturing practices in
a consistent and dependable fashion. Gearing up manufacturing
facilities for large-scale production of an assay can be a challenge,
particularly for smaller companies, who often rely on multiple
manufacturers to provide the requisite components of an assay.
Furthermore, small companies often underestimate the effort
and expense required to coordinate the manufacture of parts, kit
production, shipping of product, and subsequent technical
support, including documenting every aspect of each process.
Laboratory-Developed Tests
Laboratory-developed tests (LDTs) are in vitro diagnostic tests
that are developed, validated, and used primarily for in-house
pathology and diagnostic testing. They are intended for use by
the laboratory that develops them. However, some larger refer-
ence laboratories do offer the tests more broadly on a commer-
cial basis. These tests are not currently required to go through
FDA approval or clearance pathways, like commercially devel-
oped diagnostics tests. FDA has generally chosen to exercise “en-
forcement discretion” but this may change in the near future.
Analyte-specific reagents and LDT components are also reg-
ulated by the FDA. For the use of RUO/IUO devices for clinical
diagnostics, FDA issued a guidance recommending that they
carry a label signaling use limited to investigational purposes.
The manufacturer of an investigational product “may legally
distribute the product commercially without FDA premarket
review, as long as the marketing is only for investigational
use” [75].
Many LDTs are diagnostic molecular tests that are not avail-
able commercially and therefore are being used at geographical-
ly distant states from where the clinical specimen was obtained.
LDTs present some unique regulatory issues. Although they are
vital for healthcare, there are concerns that high-risk LDTs be
assured to provide clinically relevant information to clinicians
and their patients. Whereas many laboratories go to consider-
able lengths to validate the assays prior to making them avail-
able commercially and have developed in-house quality
assurance programs to monitor their performance, quality as-
surance data on other assays are often not readily available and
their accuracy may be difficult to assess. It is incumbent upon
the laboratory that is submitting samples for testing using an
LDT to substantiate the accuracy and performance of the test
prior to sending samples. It is important that the need for
safety and efficacy be balanced with the need for flexibility and
availability of customized tests for a local population.
The Global Regulatory Environment
The United States is not the only country that has regulations
for the marketing of in vitro diagnostic products. In Europe, the
Conformité Européenne In Vitro Diagnostic (CE-IVD) mark,
indicating clearance for use, comes with its own set of regula-
tions and requirements. Clearance for many products is “self-
declared” and is based on “data on file”; diagnostic tests for
some sexually transmitted infections, HIV-1, and other targets
have more rigorous clearance pathways. Companies planning to
market diagnostic products in countries such as Australia,
Canada, China, India, Japan, Mexico, and other countries in
South and Central America will find additional regulatory
hurdles, some of which are quite complicated and involve multi-
ple clinical trials run exclusively in that country before permis-
sion to market can be sought. Although there have been a
number of multilateral discussions among various regulatory
bodies focused on harmonizing regulatory requirements global-
ly, this is likely several years away. In the meantime, companies
must often undertake multiple clinical trials, each with its own
set of guidelines, to gain the necessary approvals to market their
products in multiple countries around the world.
Basic Research and Early-Stage Development
Diagnostic companies involved in the development of novel
tests for infectious agents range in size from a few employees to
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thousands of employees with research and development budgets
that range from thousands to billions of dollars. Many smaller
companies seek funding from a variety of sources, including
government grants, public–private partnerships, venture capital
companies, and pharmaceutical companies to finance their re-
search and development efforts. Academic partnerships are
often critical to smaller firms, many of which integrate product
development with other lines of research. In some cases, small
companies evolved from successful academic programs on
university campuses. Many NIH study sections have not given
diagnostic grants high priority. The SBIR program and public–
private partnerships between industry and the federal govern-
ment have been more fruitful, yielding a number of successful
products.
Diagnostics for Pharmaceutical Company Use
There is considerable interest in exploring the role of molecu-
lar diagnostics in clinical trials of novel antimicrobial agents.
Potential uses of rapid diagnostic tests include (1) screening
of patients with specific clinical syndromes for targeted micro-
organisms prior to, or concomitant with, study enrollment;
(2) enrichment of study population with patients with less
common infections; (3) smaller clinical trials in that more
patients enrolled would have a “proven” microbial etiology of
their illness; or (4) as companion diagnostic tests, where the
test and the drug are linked together as part of the clinical trial
and ultimately for prescribing. Evolving regulatory guidance
for the codevelopment of drugs and diagnostics currently make
this a challenging area.
Many pharmaceutical companies are searching for diagnos-
tic partners whose assays can be implemented to make clinical
trials more cost effective by preenriching for evaluable patients.
For example, a clinical trial of a novel antimicrobial agent with
activity against both MRSA and MSSA in skin and skin struc-
ture infections may want a rapid test (1 hour or less) to screen
wound specimens from potential patients to identify those spe-
cifically with MRSA infections. Such a strategy usually goes
smoothly when the diagnostic test already exists. However,
pharmaceutical companies may seek a diagnostic partner to
develop a test for a single pathogen in a body site or organ (for
example, in the lung), where multiple pathogens may be the eti-
ologic agent of disease. Here a conflict begins to emerge
between the diagnostic company that wants to develop a
product with broad clinical utility and marketability (ie, one
that detects multiple infectious agents), and the pharmaceutical
company that is interested in both a limited panel of infectious
agents (often a single organism) and a limited financial com-
mitment. Although it would appear that there would be consid-
erable synergy between pharmaceutical and diagnostics
companies that could share the costs of both development and
clinical trials, such synergies have been few and far between.
SECTION V: CHALLENGES TOADOPTION OF
DIAGNOSTIC TESTS
Clinical Challenges to Adoption
A major barrier to adoption of diagnostic tests is that tests may
not address the needs of a given clinical setting, as outlined in
Section II. Here we present additional clinical challenges to
adoption of diagnostics and potential solutions (summarized in
Table 4).
Test Availability, Performance, and Applicable Data
For some clinical conditions requiring antimicrobial therapy,
either no optimal diagnostic assay is available or poor diagnos-
tic test performance in the clinical setting or in the clinical pop-
ulation being tested limits the utility for patient management.
Because many FDA-approved or -cleared tests and LDTs have
been validated using ideal specimens from a very specific, well-
defined population, interpretation of results in real-world clini-
cal practice (eg, where patients may be on antibiotics at the
time of diagnostic testing) remains unsatisfactory for wide-
spread uptake by practitioners. In fact, acceptable standards for
positive and negative predictive values that would translate to
changes in patient management are lacking and will vary based
on the disease under consideration.
Turnaround time will also determine the utility and uptake of
diagnostic tests. Some “time-sensitive” diagnoses require immedi-
ate specific targeted therapy to avoid sequelae of the diseases or
relative toxicity of empiric treatment. These tests are best performed
near the patient as either POC tests or in rapid response labora-
tories. Conversely, for diagnoses of diseases that progress at a
much slower rate, the turnaround time is less urgent, permit-
ting the use of tests performed in centralized laboratories.
Another significant barrier to widespread uptake and use of
many diagnostic tests is the paucity of clinically applicable out-
comes data to show that use of the test in making treatment de-
cisions is superior in terms of morbidity, mortality, or cost
compared to empiric therapy. Outcomes data with clinically
relevant parameters (eg, clinical outcomes, complications, and
mortality) are critical for providers to effectively use any labora-
tory assay.
Clinical Guidelines and Clinician Education
Consensus or professional society guidelines influence how di-
agnostic tests are incorporated into clinical practice for infec-
tious diseases, but guidelines do not always explicitly include
the use of diagnostic tests. Consensus guidelines are usually
created by a panel of clinical experts to evaluate the perfor-
mance of a relevant diagnostic assay based on available litera-
ture as well as expert opinion; however, often there is no
clinical microbiology expert in the use of that test at the table. If
the use of a relevant assay is included into clinical practice
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guidelines, there is an implied “standard of care,” as well as
“standard of endorsement.” With few exceptions, when pub-
lished professional society guidelines recommend the use of a
diagnostic assay, it makes it easier for a clinician to use and
argue for the test to be covered by reimbursement.
Beyond guidelines, clinician education is a key requirement
for successful uptake and appropriate use of new diagnostic
tests; without this knowledge, clinicians will not understand the
potential value and appropriate use of new tests. Whereas grad-
uate medical education plays an important role in teaching new
healthcare providers how to use existing diagnostic tests, con-
tinuing education programs and regular interactions between
clinicians and clinical microbiologists are also vital in facilitat-
ing appropriate use of new tests and interpretation of results.
Examples of recent challenges include molecular diagnostic test-
ing for viral respiratory pathogens and the importance of appro-
priate testing practices for C. difficile testing that exclude formed
stool specimens to avoid overtreatment of colonization [76].
Recent changes and developments in rapid molecular tests have
in many cases outpaced clinician awareness and uptake. Labo-
ratorians can facilitate education of healthcare personnel in the
scope of use of a diagnostic test, interpretation, and recommen-
dations for repeated or follow-up testing through, for example,
blogs of new assays, updated specimen collection guidelines,
and presentations to key stakeholders. Infectious diseases cli-
nicians serve as a critical liaison between healthcare providers
and the clinical microbiology lab, and engaging their expertise
will assist in determination of the best diagnostic test and
interpretation of laboratory results, leading to improved patient
care.
Challenges in Resource-Limited Settings
Limited resources and access may impact the availability of di-
agnostic tests in both resource-limited settings around the
world as well as rural and other resource-limited settings in the
United States. In many cases, for example, the newly available
rapid molecular tests, cost is high and thus the tests are not
available as standard of care, or they may not be billed as a re-
imbursable test. Some new technologies may be too complex
for all levels of healthcare. For complex testing, volume of
testing at a particular site is sometimes too low to ensure com-
petency of testing by laboratory personnel. However, this may
be less of an issue for newer technologies that are more user-
friendly. In addition, the robustness of technology breakage
and the needs for maintenance are too onerous for many set-
tings.
Technological needs for specimen preparation and transport,
such as the need for high-speed centrifuge, refrigeration of
specimens during transport, or the inability to batch specimens
may also affect the feasibility of their use. Distance of reference
laboratories and specimen transport remain a significant barrier
for resource-limited settings, although creative approaches for
transport (such as using public buses and motorbikes and text
messaging for result transmission) and sample preparation
(such as dried blood spots) are starting to have an impact.
Nonetheless, even where these opportunities currently exist,
Table 4. Examples of Clinical Challenges to Use of Diagnostic Tests
Challenge Example Explanation Solution
Limited availability Varicella, measles Diagnosis based on clinical suspicion;
antibody detection tests are inaccurate,
especially early in the course of illness
Consensus guidelines
Poor performance
in clinical setting
Rapid influenza antigen
detection tests
Pooled sensitivity only 62%with greater
sensitivity for influenza in children
Rapid molecular diagnostic assays
Turnaround time Bacterial culture and
antimicrobial
susceptibility testing
Typically ranges from 24 to 72 hours Rapid testing, eg, molecular diagnostics,
MALDI-TOFMS
Lack of outcomes
data
Rapid molecular testing Limited data on morbidity and mortality
benefit of molecular panels for
respiratory pathogens
Additional outcomes research
Guidelines Community-acquired
pneumonia
2007 IDSA/ATS guidelines do not
recommend routine use of sputum
culture and diagnostic tests due to poor
performance
Inclusion of clinical microbiology experts in
development of guidelines; additional
research on alternative diagnostic methods
directly from clinical specimens including
molecular diagnostics
Clinical education Acceptability and
interpretation of
molecular tests
Interpretation of test results requires
knowledge of principles of PCR
Collaboration between clinical microbiology
laboratory and clinical specialties; additional
training of healthcare providers
Abbreviations: IDSA/ATS, Infectious Diseases Society of America/American Thoracic Society; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry; PCR, polymerase chain reaction.
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efficiency of specimen transport to a centralized lab is some-
times lacking. Furthermore, there remains variability in the ro-
bustness of the information technology infrastructure for
results reporting, including interfacing of diagnostic instru-
ments and rapid delivery of results via the laboratory informa-
tion system and electronic health records.
Financial Challenges to Use of Diagnostic Tests
Reimbursement for Diagnostic Device Use
Difficulties and concerns regarding reimbursement for new or
expensive diagnostic tests may hamper innovation and are a
significant challenge to the widespread use of these technolo-
gies. Reimbursement in the United States involves (1) coding of
health services or conditions to determine payment, (2) cover-
age by third-party payers, and (3) determination of level of
payment. Codes for diagnostic tests are developed under the
CPT system maintained by the American Medical Association
(AMA). The International Classification of Diseases, Ninth Re-
vision, Clinical Modification—ICD-9-CM (or the soon to be im-
plemented ICD-10)—codes for patient diagnoses are used in
combination with CPT codes in billing.
Obtaining new CPT codes or revising existing ones to ac-
commodate emerging diagnostic tests is a complex and often
lengthy process that can take up to 2 years. Applications for
new CPT codes must be submitted to the AMA CPT Editorial
Panel according to a specific schedule 3 times per year, and
must be supported by the CPT Advisory Committee and other
stakeholders. Furthermore, once obtained, coverage of these
tests may vary by insurer, and current coding and payment
mechanisms often do not reflect the value of new diagnostic
tests.
Payment for laboratory tests performed on inpatients depends
on the type of insurance covering the patient (eg, HMO or
other managed care organizations, Medicare, Medicaid, indem-
nity, and self-pay) and the specifics of the payment contract
between the healthcare provider and the insurer. Laboratory
tests performed for Medicare inpatients are part of the Diagno-
sis Related Group payment method, and separate payment for
individual laboratory tests is generally not available [77]. Similar
bundled payment is mandated for many non-Medicare patients
by insurance and hospital contracts.
For outpatient tests with CPT codes, the Medicare Coverage
Advisory Committee advises CMS regarding diagnostic test
coverage, including determination of sufficient evidence, as
well as health benefit. Medicare pays for outpatient laboratory
tests according to fee schedules. However, most Medicare reim-
bursement decisions are made locally rather than at the nation-
al level. Coverage for diagnostic tests varies regionally, and
given the lack of standards in determining coverage, this can
pose challenges for development and dissemination of a new
diagnostic product. CMS in 2001 created policies to address
inconsistencies in coverage for 23 tests, including hepatitis,
HIV, and bacterial urine culture.
Payments for new diagnostic tests are often assigned by
cross-walking (when CMS decides a new test is similar to an ex-
isting clinical test) or gap filling (the use of local payment data
to assign a new test code payment); novel diagnostics are a chal-
lenge given that CMS may not easily be able to determine whether
to use cross-walking or gap filling to set reimbursement. Collec-
tion of gap filling data is time consuming, and therefore most
new test code prices are assigned using cross-walked codes,
which frequently receive lower payment rates.
Compliance and billing remain challenges for clinical labora-
tories and may also limit the availability of testing. In some
cases, the reimbursement does not cover the cost of the test,
which limits laboratory interest in offering the test and may
limit test availability and use by clinicians. In other cases the
charge may be high but leave considerable cost to the patient,
thus limiting clinicians from ordering the test routinely. Reim-
bursement is essentially nonexistent for tests in development.
Until recently, MALDI-TOF instruments and databases were
available as research use only (RUO), limiting billing for public
and private payers. At the federal and state level, laboratories
typically cannot bill for RUO tests and current guidelines do
not allow for the use of RUO instruments and reagents in the
clinical laboratory.
Cost-effectiveness
Cost-effectiveness is another important consideration for use of
a diagnostic test, as decision makers in healthcare systems con-
sider the relative costs and outcomes of diagnostic testing. Hos-
pitals and clinicians are now facing scrutiny of costs of therapy,
including the evaluation of physician-specific management
costs. Clinicians and administrators are faced with decisions to
determine when a test is indeed worth the cost. When assessing
the cost-effectiveness of laboratory tests, it is important to eval-
uate the cost savings to the healthcare system, as the newer mo-
lecular tests may increase the cost to the laboratory while
leading to decreased length of stay, reduced use of antibiotics,
or other savings that more than offset the additional cost of the
test. Unfortunately many institutions have a “siloed” approach
to budgeting that leads them to consider only laboratory costs
and see the novel tests as expensive compared to traditional
methods.
Studies establishing the cost-effectiveness of traditional diag-
nostic tests are rather limited; the widespread use of molecular
methods has led to an increased number of studies examining
the cost savings associated with these tests. Molecular tests with
increased sensitivity compared to an EIA led to better detection
of C. trachomatis infections in women, resulting in the reduc-
tion of complications such as pelvic inflammatory disease and
ectopic pregnancy and an overall cost savings, even though the
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cost of the molecular test was significantly higher than the cost
of the EIA [78, 79]. These findings were followed by studies
assessing the clinical impact of RT-PCR for the detection of en-
terovirus in the CSF of pediatric patients with aseptic meningi-
tis. Multiple studies have shown a reduction in antibiotic use,
hospital costs, ancillary tests, and/or length of hospital stay
when the enterovirus testing is performed within 24 hours of
specimen collection [15, 54, 56].
A 2010 historically controlled study illustrated the impor-
tance of ensuring clinical response to rapid testing. A rapid (1
hour) PCR assay for S. aureus and MRSA was performed on
blood cultures with Gram stain results showing gram-positive
cocci in clusters. The results were immediately paged to both
the responsible physician and an infectious diseases pharma-
cist. Compared to controls from a time period before the avail-
ability of PCR, the mean time to switch from empiric
vancomycin to either nafcillin or cefazolin for MSSA bactere-
mia decreased by 1.7 days. After implementation of S. aureus
PCR testing, the mean length of hospital stay decreased by 6.2
days and the mean per patient hospital cost decreased by
$21 387 [80]. In contrast, another study with a similar design
failed to show a reduction in time to optimal antibiotic therapy.
Benefits were not achieved due to failure to facilitate actions on
the part of physician providers [81]. Similar to the first study,
the rapid detection of Candida species directly from positive
blood cultures and rapid reporting to a healthcare provider or
pharmacist allowed the targeted use of antifungal therapy re-
sulting in a reduction in the use of echinocandin therapy and
an overall cost savings [51, 52, 82].
MALDI-TOF MS instruments are recently available for use in
clinical microbiology laboratories. Several studies have shown
that incorporating the use of MALDI-TOF MS for the identifica-
tion of bacteria and yeast provided results several days earlier
compared to standard identification methods with a substantial
reduction in reagent and labor costs [53, 57]. Combined with an-
timicrobial stewardship interventions, MALDI-TOF MS can
reduce unnecessary days of antibiotic treatment [83].
More work needs to be done to assess the cost-effectiveness
of diagnostic tests, and as the availability of rapid tests increas-
es, it is imperative to determine which tests will impact clinical
decisions in a meaningful way. The success of diagnostic tests
requires that, in addition to being accurate and clinically rele-
vant, the test be performed in a timely manner with rapid com-
munication of results to the team providing care to the patient.
Operational Challenges to Use of Diagnostic Tests
Transportation and specimen handling requirements can be
additional barriers to use of diagnostic tests. In contrast to
other areas of clinical pathology, diagnostic microbiology labo-
ratories are unique in the variety of specimens that are submit-
ted and processed, and in the lack of highly automated
instruments to test primary specimens directly for the most
common pathogens. Microbiology laboratories must have de-
tailed procedures for specimen collection and ensure prompt
and appropriate transport, particularly if testing is not per-
formed on-site. For preanalytical specimen processing, “sim-
plicity is usability.” The more difficult it is to collect, process,
and transport a specimen, the lower the likelihood it is to be
done correctly. Here, infectious diseases clinicians can serve an
important role by advising other healthcare providers on ob-
taining optimal samples and diagnostic testing. The ideal speci-
men would be collected at room temperature and in such a
vessel that permitted room temperature transportation without
time limitations or processing before transporting. In addition,
laboratories must develop and/or verify preanalytical and ana-
lytical procedures that do not compromise assay performance
for each matrix type tested.
Currently, diagnostic testing in clinical microbiology labora-
tories is evolving and microbiologists are faced with supporting
classical culture and other methods with less than ideal perfor-
mance characteristics while embracing and verifying novel
technologies that are in some cases more complex and usually
more expensive. Some of the tests on current molecular plat-
forms take an entire day to perform and require technologists
who are highly trained in molecular techniques. Depending on
the assay, laboratory space may need to be reconfigured to
support the platform and to prevent laboratory contamination.
If the volume of testing is low, then practical issues such as cost
and employee proficiency must be considered for the larger
platforms. Historically, single test instruments have been costly
both in terms of initial capital and cost per reportable result,
and many smaller laboratories therefore did not embrace them.
However, the target is now moving, and the value of these in-
struments is being increasingly recognized.
Microbes are evolving and the clinical microbiologist must
constantly be on the alert for unusual pathogens. The crisis in
medical technology education, an aging workforce, and the dif-
ficulty in recruiting and retaining technologists have resulted in
fewer technical specialists in anaerobic bacteriology, mycology,
mycobacteriology, and parasitology—subspecialties that still
rely upon interpretation of culture-based and microscopic
methods. As a result, many facilities outsource this work to
large reference laboratories, compromising specimen integrity
and potential recovery, and/or delaying identification that can
substantially impact patient care. Some tests may be sent to
public health laboratories, where there is expertise.
Although many of the newer technologies are simpler and
can be operated by less skilled personnel, the consequence is
that less knowledge about the biology of infectious diseases is
found in the laboratory. Ensuring proper quality assurance is
instituted, knowing when the results are questionable, and trou-
bleshooting abilities can be compromised when less technically
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challenging tests are used by less technically savvy personnel.
Advancement of the status, perception, and financial compen-
sation for persons entering the field of laboratory medicine will
be essential to ensure a continuance of highly trained laborator-
ians to replace the aging workforce.
Assay Verification and Validation
As laboratories embrace new technologies, under CLIA, verifi-
cation of accuracy and performance is required. The process
follows a simpler pathway for qualitative assays than for quanti-
tative assays, yet the exact requirements for successful verifica-
tion of a commercial product can be elusive. A number of
professional societies have weighed in on what constitutes an
acceptable verification or validation study, but those guidelines
are often conflicting. Verification studies are not difficult for or-
ganisms that are prevalent, but for the rare pathogen or disease,
finding clinical material may be difficult. In addition, often lab-
oratories are faced with requests to test a matrix for which the
assay does not have an FDA indication, yet may be a common
specimen received in the laboratory for diagnosis of that infec-
tion. For example, given the variability in samples obtained by
bronchoscopy, diagnostics companies may not include those
specimens among the approved sources for respiratory virus
detection when submitting their applications to the FDA. Yet,
this may be the best specimen for some of our sickest patients
or for certain syndromes. Either the laboratory cannot offer the
test (or report the specific analyte) for an alternative sample
type or must go through great expense and effort to validate the
specimen type.
For the verification of multiplex panels, the laboratory may
need to find enough specimens containing 12–22 different
pathogens (depending upon the assay). This requires tremen-
dous resources and can significantly delay assay implementa-
tion. The laboratory faces a dilemma when a target on a panel
(such as a novel virus in a respiratory panel), which has yet to
be verified, becomes positive. What the laboratory should do in
this instance is hotly debated and depends in many instances
on the clinical, social, or public health impact of a correct or an
incorrect result (eg, the reporting of a false-positive test for in-
fluenza A[H7N9]). As with alternative sample types, either the
laboratory cannot offer the test (or report the specific analyte),
or must go through great expense and effort to validate the
analyte. Moreover, for the verification/validation of rare ana-
lytes, materials may not even be available for such studies.
Another challenge to implementing newer assays is that
often the new assay is more sensitive than the existing reference
method. The problem then becomes how to resolve results that
are positive by the new method, but negative by the “gold stan-
dard.” In some cases the old gold standard (eg, C. trachomatis
culture or C. difficile EIA testing) is called into question.
Ideally, the laboratory would have access to the clinical
presentation of the patient as part of the verification or valida-
tion process, but there are major barriers in most cases to ob-
taining this information. In the case of FDA clinical trials,
providing clinical data may require obtaining informed consent,
which adds expense to the trial. Additionally, many laborato-
ries with extensive experience in conducting FDA trials may
not have the infrastructure to obtain consent and therefore
would not be able to participate, access to the patients’ records
may not be possible as they may be in a facility some distance
from the trial laboratory, and other institutional barriers may
exist. Laboratories wishing to evaluate new technologies with a
clinical partner outside of the FDA approval process often find it
increasingly difficult to find funding sources to support the eval-
uation, given the cost of testing and the lack of reimbursement.
RECOMMENDATIONS ANDCONCLUSIONS
Diagnostics have had a tremendous impact on the management
of patients with infectious diseases and are essential for out-
break detection and response, and public health surveillance.
As we transition from conventional culture and antigen detec-
tion methods to newer molecular methods, the ability to
provide accurate results in a clinically meaningful time frame,
near the point of care, has never been greater. Diagnosing HSV
encephalitis without molecular tests or managing patients
without viral load values are distant memories, as the molecular
revolution of the past 20 years dramatically changed the man-
agement of patients with viral infections and now expands to
bacterial and fungal infections. One technology, MALDI-TOF
MS, is poised to completely change the identification of bacteri-
al and fungal pathogens, allowing for identification within a
few minutes after growth on media.
Yet despite these extraordinary technological advances, chal-
lenges remain. FDA approved or cleared molecular tests are
available for a remarkably limited number of pathogens and
generally diagnostics are notably underutilized. Some of the
major issues that prevent broad adoption of diagnostic tests
include slow turnaround time, poor test performance charac-
teristics, high complexity testing that cannot be easily adopted
in many clinical settings, lack of understanding of the value of
diagnostics, limited access to testing, and high cost. Clinicians
need access to rapid, simple tests that can rule in or out infec-
tion, diagnose a syndrome (sepsis, pneumonia), or identify a
specific pathogen or resistance determinant. When such a test
is available, it can dramatically improve patient care and reduce
healthcare costs, as has been shown for molecular testing for
the diagnosis of enteroviral meningitis. More tests that meet
these standards are desperately needed.
In this policy paper, IDSA reviews the current state of diag-
nostics and the unmet clinical needs, assesses new technologies
that could address these needs, and investigates barriers to the
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Table 5. Recommendations to Accelerate Development of Improved Infectious Diseases Diagnostics and Integration Into Clinical Care
Primary Actors Recommended Action Section
Stimulate diagnostics research and development
Federal funding bodies Innovative funding mechanisms and clinical research infrastructure
• Increased NIH funding through SBIR program and U01 funding
mechanism
• NIH study sections should have appropriate expertise to evaluate
feasibility and clinical applicability along with scientific merit
• Development of biorepositories or other infrastructure to facilitate the
procurement of critical clinical specimens (see Appendix B)
R&D Challenges (Section IV)
Congress Increased funding to agencies and programs that address unmet
diagnostic needs.
• To NIH for diagnostics research, including the SBIR diagnostics
program at NIAID and the Point-of-Care Technologies Research
Network at NIBIB
• To BARDA for the advanced development of innovative infectious
diseases diagnostics
• To the CDC AMD initiative
Unmet Needs, R&D Challenges
(Sections II, IV)
Congress • Enact legislation to support a tax credit to cover 50% of clinical research
costs for qualifying rapid diagnostics
• Enacting the 21st Century Global Health Technology Act (H.R. 1515),
which will strengthen health R&D programs at USAID and require no
new funding
Unmet Needs (Section II)
Congress, Administration,
and federal funding
bodies
Prioritize funding and incentives for diagnostics with the following
characteristics:
• Test directly from accessible, minimally invasive clinical specimens
• Able to rule out infection with high certainty (eg, ≥98% negative
predictive value)
• Incorporate biomarkers that can indicate host response to pathogen or
further classify infectious processes into categories (eg, bacterial,
fungal, viral, or parasitic)
• Panels targeting CNS infections, sepsis and bloodstream infections,
respiratory tract infections, and fungal pathogens
• Special considerations for pediatric use, especially for biomarkers and
syndromic panels
• Pathogen-specific diagnostics linked to drug resistance information
• Rapid diagnostics that substantially improve upon the “time to result”
metric
• Point-of-care diagnostic testing that allows for usage in varied clinical
settings
Unmet Needs, New Technologies
(Sections II, III)
Expedite integration of improved diagnostic tests into patient care
CMS, in coordination with
the Office
of the National
Coordinator for
Health IT, and in
collaboration with
healthcare systems and
diagnostic
companies
• Encourage healthcare systems to improve electronic medical record
systems, including reporting of lab results to health departments
• Provide incentives for healthcare facilities to formmultidisciplinary
teams to develop protocols for responding to clinically significant test
results
• Healthcare systems should use clinical guidelines from IDSA and other
professional societies to guide patient management decisions
regarding diagnostics use
• Healthcare systems should be encouraged to develop cost-
effectiveness models that assess the impact of diagnostics on all facets
of patient care, eg, mortality, length of stay, use of antimicrobials, and
isolation procedures
• Diagnostic companies should work with healthcare systems to ensure
that new diagnostics integrate into laboratory workflow practices
Unmet Needs, Adoption
Challenges (Section II, V)
Congress and the
Administration
• Fund information technology solutions for data integration and
dissemination, to be developed locally within healthcare institutions
Unmet Needs, Adoption
Challenges (Sections II, V)
Federal funding bodies, in
collaboration with
industry
• Outcomes research to determine whether use of specific tests
improves patient outcomes and/or resource utilization
Unmet Needs, Adoption
Challenges (Sections II, V)
Address regulatory challenges to diagnostics R&D
Congress and NIH,
working with
other stakeholders
• Clarify and revise conflict of interest policies to allow collaboration
between diagnostics companies, diagnostic laboratories, and key
opinion leaders, as their expertise is necessary to conduct FDA
licensing trials
R&D Challenges (Section IV)
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Table 5 continued.
Primary Actors Recommended Action Section
Department of Health and
Human
Services
• Withdraw the draft proposal to institute a new informed consent
requirement for research with de-identified residual clinical samples,
outlined in the 2011 Advanced Notice of Proposed Rulemaking for
human subjects research protections (ie, the Common Rule), as it
would severely limit the conduct of diagnostics research
R&D Challenges, Adoption
Challenges (Sections IV, V)
Congress • Provide incentives and support for institutions to save de-identified
specimens when possible for the purposes of new test development,
FDA licensing trials, and assay verification and validation
R&D Challenges, Adoption
Challenges (Sections IV, V)
FDA • CDRH should revise the guidance for RUO/IUO devices and permit use
in cases where there are no other diagnostic options
• CDRH should exercise its flexibility and exempt companies from
redemonstrating the clinical validity of a novel diagnostic product after
multiple studies have been conducted for similar products
• CDRH and CDER should provide greater clarity in guidance for the
codevelopment of drugs and diagnostics
• Assist in the development of strategies to preserve specimens for
public health surveillance purposes, eg, by asking developers of new
technologies to include a public health “plan”with their submission
R&D Challenges, Adoption
Challenges (Sections IV, V)
Ensure appropriate levels of reimbursement for diagnostics testing
CMS • Eliminate the wide regional variations in the reimbursement of tests and
ensure that reimbursement covers the cost of testing
• Simplify, expedite, and increase the transparency of the process for
assigning new CPT codes and subsequent incorporation of new codes
for laboratory tests into CLFS
Adoption Challenges (Section V)
Congress • Enact the Diagnostic Innovation Testing and Knowledge Advancement
Act of 2013 (H.R. 2085 in the 113th Congress) to improve the process
of Medicare payment rate determination for diagnostic testing
Adoption Challenges (Section V)
Encourage adoption of new tests
CMS, in concert with
professional
societies and labs
• Harmonize recommendations from CMS through the CLIA regulations
and from various professional societies and organizations (eg, CLSI,
College of American Pathologists) to provide laboratories with greater
clarity of the processes for clinical validation or verification for new
assays
• Stakeholders should collaboratively develop guidelines on how to
establish reference methods for new technologies that are more
sensitive and specific than the existing “gold standard”
• CMS should discourage facilities that do not receive enough specimens
to maintain competency and accuracy from conducting highly complex
diagnostic testing technology
Adoption Challenges (Section V)
Diagnostic companies • Convert highly complex assays to moderately complex tests that can be
performed in a variety of clinical settings using “walk-away technology”
• Promote industry training in new technologies for the laboratory
workforce
Adoption Challenges (Section V)
Congress and HRSA, with
professional societies
• Support the recruitment and retention of clinical microbiologists and
medical technologists
Adoption Challenges (Section V)
Educate healthcare providers on the use of diagnostics
AHRQ and HRSA,
working with
healthcare
institutions and
professional societies
• Fund and encourage strengthened educational programs to
disseminate the results of diagnostics-focused health sciences
research and to inform physicians about the utility of available tests
• Professional societies, educational institutions, and other entities
involved in the education of clinicians should ensure that education
includes the performance of diagnostic tests, interpretation of test
results in individual clinical settings with varied patient populations,
available guidelines, and cost of testing
• Professional societies and other organizations should include clinical
microbiology experts in the development of clinical practice guidelines
that make recommendations on the use of diagnostic tests
Adoption Challenges (Section V)
Abbreviations: AHRQ, Agency for Healthcare Research and Quality; AMD, Advanced Molecular Detection; BARDA, Biomedical Advanced Research and
Development Authority; CDC, Centers for Disease Control and Prevention; CDER, Center for Drug Evaluation and Research; CDRH, Center for Devices and
Radiological Health; CLFS, Clinical Laboratory Fee Schedule; CLIA, Clinical Laboratory Improvement Amendments; CLSI, Clinical and Laboratory Standards
Institute; CMS, Centers for Medicare and Medicaid Services; CNS, central nervous system; CPT, Current Procedural Terminology; FDA, Food and Drug
Administration; HRSA, Health Resources and Services Administration; IDSA, Infectious Diseases Society of America; IT, information technology; NIAID, National
Institute of Allergy and Infectious Diseases; NIBIB, National Institute of Biomedical Imaging and Bioengineering; NIH, National Institutes of Health; R&D, research
and development; RUO/IUO, research use only/investigational use only; SBIR, Small Business Innovation Research; USAID, US Agency for International
Development.
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development and adoption of new diagnostics. A broad range
of recommendations are provided to address the identified
challenges (Table 5). There needs to be a comprehensive com-
mitment to developing technologies that will allow testing to
move from highly complex laboratories to all laboratories or to
the bedside, creating programs to educate clinicians on the proper
use and interpretation of tests, investing in cost-effectiveness and
clinical outcomes studies, and further advancing information
systems to allow not only for the rapid communication of test
results to healthcare providers and public health agencies, but
also for a rapid action in response to the test result. It is impor-
tant to consider the public health implications of these in-
novations as they are developed to ensure that there are no
unintended negative effects on our capacity to identify, respond
to, and track infectious public health threats.
Progress will require the engagement and coordination of a
number of stakeholders including funding agencies, regulatory
agencies, public health agencies, diagnostic companies, health-
care systems, clinical microbiology laboratory professionals, cli-
nicians, and professional societies. Congress must play a role in
increasing funding for diagnostics research and enacting legis-
lation that addresses identified challenges. Successful implemen-
tation of these recommendations will require a commitment
from all stakeholders, and will open the door for remarkable pro-
gress in the field of diagnostics and resulting impact on many in-
fectious diseases. As technologies advance, there is a critical
window of time to harness and direct development of new diag-
nostics to benefit patients. The goal is not just to create more
tests, but to develop rapid, reliable, accurate, simple tests that will
reduce time to a diagnosis and truly improve the quality of care
and patient outcomes while reducing healthcare costs.
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APPENDIX B: PROTOTYPE FOR
ESTABLISHMENTOFAN INFECTIOUS
DISEASES CLINICAL SPECIMEN REPOSITORY
HSV encephalitis will serve as an example of how a targeted
specimen repository may assist in the FDA clearance of a diag-
nostic test. It has been known since the landmark study by
Lakeman et al in 1995 [14] that PCR testing of CSF is a very
sensitive and specific diagnostic tool for HSV encephalitis, es-
sentially eliminating the need for brain biopsy. Yet, nearly 20
years later, there is not an FDA-cleared test for this indication,
even though molecular testing is considered the standard of
care for the diagnosis of HSV encephalitis. In the absence of an
FDA-cleared test, clinicians rely on LDTs. One of the challeng-
es of the approval process is that HSV encephalitis is a rare
disease, with any given large medical center treating a few cases
annually. The development of a specimen repository could be
very useful for companies interested in developing such a test. In
fact, there are several molecular tests for detecting genital tract
HSV that have been FDA cleared. If FDA-defined characterized
Appendix A: LIST OF ABBREVIATIONS
AHRQ – (HHS) Agency for Healthcare Research and Quality
AMA – American Medical Association
AMD – (CDC) AdvancedMolecular Detection
ASR – analyte-specific reagents
AsTeC – Aspergillus Technology Consortium
BAL – bronchoalveolar lavage
BARDA – (HHS) Biomedical Advanced Research and Development
Authority
CAP – community-acquired pneumonia
CDC – (HHS) Centers for Disease Control and Prevention
CDER – FDACenter for Drug Evaluation and Research
CDRH – FDACenter for Devices and Radiological Health
CLFS – Clinical Laboratory Fee Schedule
CLIA – Clinical Laboratory Improvement Amendments
CLSI – Clinical and Laboratory Standards Institute
CME – continuing medical education
CMS – (HHS) Centers for Medicare and Medicaid Services
CMV – cytomegalovirus
CNS – central nervous system
CoNS – coagulase-negative Staphylococcus
CPT – Current Procedural Terminology
CSF – cerebrospinal fluid
DRG – diagnosis related groups
ED – emergency department
EIA – enzyme immunoassay
ELISA – enzyme-linked immunosorbent assay
ESI-TOF – electrospray ionization time of flight
EUA – Emergency Use Authorization
FDA – (HHS) Food and Drug Administration
GME – graduate medical education
HAP – hospital acquired pneumonia
HBV – hepatitis B virus
HCAP – healthcare-associated pneumonia
HCV – hepatitis C virus
HHS – Department of Health and Human Services
HIV – human immunodeficiency virus
HPV – human papilloma virus
HSV – herpes simplex virus
HRSA – (HHS) Health Resources and Services Administration
ICD – International Classification of Diseases
ICU – intensive care unit
IDSA – Infectious Diseases Society of America
IFI – invasive fungal infection
IP – intellectual property
IRB – institutional review board
IVD – in vitro diagnostic
KPCs – Klebsiella pneumoniae carbapenemases
LAMP – loop mediated amplification
LDT – laboratory developed test
MALDI-TOF MS –matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry
MERS-CoV –Middle East respiratory syndrome coronavirus
MOC –maintenance of certification
Appendix A continued.
MRSA –methicillin-resistant Staphylococcus aureus
MSSA –methicillin-susceptible Staphylococcus aureus
NAAT – nucleic acid-based amplification technology
NASBA – nucleic acid sequence based amplification
NDM-1 – New Delhi metallo-beta-lactamase-1
NGS – next generation sequencing
NIAID – (NIH) National Institute of Allergy and Infectious Diseases
NIBIB – (NIH) National Institute of Biomedical Imaging and
Bioengineering
NIH – (HHS) National Institutes of Health
ONC – (HHS) Office of the National Coordinator for Health
Information Technology
PCORI – Patient-Centered Outcomes Research Institute
PCR – polymerase chain reaction
PCT – procalcitonin
POC – point-of-care
PMA – pre-market approval
PFGE – pulsed field gel electrophoresis
R&D – research and development
RSV – respiratory syncytial virus
RT-PCR – reverse transcriptase polymerase chain reaction
RUO/IUO – research use only/investigational use only
SBIR – Small Business Innovation Research
SDA – strand displacement amplification
SIRS – systemic inflammatory response syndrome
TATFAR – Transatlantic Task Force on Antimicrobial Resistance
TMA – transcription mediated amplification
USAID – United States Agency for International Development
VAP – ventilator-associated pneumonia
VRE – vancomycin-resistant enterococci
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CSF specimens were available, these tests could be evaluated to
determine if the proposed diagnostic assays have adequate sensi-
tivity and specificity for the diagnosis of HSV encephalitis. A
process for establishing such a repository is outlined below and
would be done in collaboration with the NIH, FDA, and/or IDSA.
• Establish a group of collaborators willing to provide clinical
data and specimens to the repository. This could be done by col-
laborating with IDSA and the Pan American Society for Clinical
Virology to identify participating sites. Given that the number of
cases at any given site is low (approximately 1–5 annually), it is
likely that as many as 40–50 sites will need to be identified to com-
plete the data and specimen collection within 12–18 months.
However,giventhelowvolume,thecollectionofclinicalinformation
and specimens would not be burdensome to any collaborator.
• Identify a site where the repository will be housed, likely
one of the clinical sites, and establish specific criteria for main-
taining the repository. Preferably, the repository site would
have experience in document control of samples and the main-
tenance of repositories to ensure integrity of the samples and
clinical data. If not, criteria will be established by which the se-
lected repository site must be compliant.
• Create a clinical case form defining patient demographics,
clinical symptoms, laboratory and radiographic data, and treat-
ment. This would be done in collaboration with the FDA, so
that completed case forms contain all the needed information
for the FDA clearance process. This process would also include
a standardized clinical case definition of HSV encephalitis,
relying on the above criteria as well as the laboratory-developed
HSV PCR results used in real time for clinical decisions.
• Ideally, testing will be done on specimen volume remain-
ing after routine clinical testing, avoiding the need for a second
lumbar puncture. Specific criteria will need to be defined re-
garding the volume of CSF needed, conditions for local storage,
and shipping to the repository site.
• Once an adequate number (eg, 50–100) of positive speci-
mens are collected and approved in collaboration with the
FDA, companies will be notified of specimen availability. Speci-
men collection can continue for several years to ensure that
multiple companies can conduct a study.
• There may be a need to establish a review committee, com-
prised of collaborators from clinical sites, to assess company re-
quests for specimens and assure that tests have been adequately
validated prior to releasing specimens and clinical case forms. Alter-
natively, the FDA could determine that the analytical performance
of the test meets specific criteria prior to the release of specimens.
The goal is to avoid using the specimens on tests that have not been
appropriately validated, so that a test(s) is cleared within a few years.
• The financial support for the project would include clerical
and operational support for the center maintaining the repository
(less than a full-time equivalent); coordinator support for IRB sub-
mission, maintenance, and fees; and salary support (20%) for the
individual coordinating the study, organizing the meetings with the
FDA, and responding to requests for specimens. Minimal support
would be needed by the individual sites (IRB submission and fees),
as they would be expected to collect just a handful of specimens
annually, and provide case report forms for each sample submitted.
Initial startup costs for establishing the repository would be solicit-
ed by grants from the NIH, CDC, and companies with interest in
obtaining FDA clearance for in vitro diagnostic tests. Thereafter,
companies will be charged an amount for the specimens to defray
the total costs for supporting the repository. The final goal would
be to have a financially self-sustaining repository.
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